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Heart disease is a leading cause of death and disability and is a major contributor to healthcare 
costs. Many forms of heart disease are caused by abnormalities in the electrical function of heart 
muscle cells or the cardiac conduction system. Electrocardiographic Imaging (ECGI) is a 
noninvasive modality for imaging cardiac electrophysiology. By combining recordings of the 
voltage distribution on the torso surface with anatomical images of the heart-torso geometry, 
ECGI reconstructs voltages on the epicardium. This thesis applies ECGI to novel studies of 
human heart function and disease and explores new combinations of ECGI with additional 
imaging modalities. 
ECGI was applied in combination with late gadolinium enhancement (LGE) scar imaging MRI 
in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC carries a high 
risk of sudden cardiac death, and the hallmark feature of ARVC is the progressive replacement 
of healthy myocardium with fibrous and fatty tissue. By combining ECGI and LGE in ARVC 
patients we found that there are signs of conduction abnormalities before structural abnormalities 
can be detected in ARVC patients. Electrical and structural abnormalities in ARVC patients co-
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localized. We also found that PVCs, potential triggers for arrhythmia, originated in regions of 
structural and electrical abnormalities. 
ECGI was applied in combination with speckle tracking echocardiography (STE) to 
longitudinally image heart failure patients undergoing cardiac resynchronization therapy (CRT). 
STE is an echocardiographic technique for measuring strain (contraction) in the heart. CRT is a 
highly effective treatment for heart failure, however, around 30% of patients do not respond to 
the treatment. ECGI was more effective for predicting response to CRT than the current standard 
ECG criteria or STE indices. The timing of peak contraction in STE did not accurately reflect the 
electrical activation sequence. CRT caused improvements in contraction that persisted even 
when pacing was disabled. CRT prolonged repolarization at the site of the LV pacing lead, 
which may increase the risk of arrhythmia in CRT patients. 
The above studies contribute novel observations of human disease physiology and demonstrate 
the clinical feasibility and effectiveness of ECGI for noninvasive assessment of ARVC and CRT. 
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Chapter 1: Introduction 
 
1.1 Heart Disease and Electrophysiology 
Heart disease is a leading cause of death and disability and is a major contributor to healthcare 
costs 1. The pumping function of the heart is controlled by synchronized contractions of heart 
muscle cells called cardiomyocytes. Cardiomyocyte contractions are controlled by changes to the 
voltage gradient across the cell membrane. The characteristic membrane voltage signal 
associated with cardiomyocyte contraction is called the cardiac action potential. The first phase 
of the action potential is an increase in membrane voltage known as depolarization. 
Depolarization begins the process of cardiomyocyte contraction through a process known as 
excitation-contraction coupling. The membrane voltage remains elevated and contraction 
continues through the plateau phase of the action potentials. Finally, the membrane voltage 
returns to resting levels and contraction ends due to a process known as repolarization. All 
phases of the cardiac action potential are controlled by a delicate balance of ionic current flow 
through specialized transmembrane proteins known as ion channels. In order for the heart to 
pump blood efficiently, heart muscle cells must contract synchronously. Synchronization of 
cardiomyocyte contractions is accomplished by a specialized conduction system within the heart 
and electrical coupling between adjacent cells. When cardiomyocyte action potentials are 
coordinated by this cardiac conduction system, the collective action potentials of all contracting 
cells result in a voltage signal that can be measured from the body surface. 
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1.1.1 Electrocardiogram (ECG) 
Recordings of the electrical activity associated with cardiac contraction were first made in the 
1800s. The characteristic voltage signal on the body surface was named the “electrocardiogram” 
(abbreviated ECG or EKG, interchangeably) by Willem Einthoven, who won the Nobel prize in 
1924 for his research on the ECG 2. While the electronics for recording the ECG have improved 
considerably (Einthoven’s ECG recording apparatus weighed over 600 pounds), ECG recordings 
have evolved very little over the past 50 years. The current standard of practice is the 12-lead 
ECG, which records the cardiac electrical activity from standardized locations on the chest and 
limbs. 
1.1.2 ECG Abnormalities and Arrhythmia 
Many forms of heart disease are associated with ECG abnormalities. Alterations to any aspect of 
the conduction system in the heart or the cardiac action potential can lead to abnormal ECG 
findings. There are many mechanisms that cause these alterations, including structural damage 
caused by heart attacks, genetic mutations that affect ion channels or other important structures, 
and progressive heart diseases. Alterations to the normal ECG rhythm are known as arrhythmias 
and range in severity from benign to imminently life-threatening. The most important diagnostic 
tool for arrhythmias is the ECG. 
1.2 Electrocardiographic Imaging 
ECG recordings from the body-surface reflect the electrical activity of the entire heart, with 
regions close to the recording electrodes having a larger contribution to the signal than more 
distant regions. While the ECG is massively important to clinical cardiology, its resolution is 
limited by the distance of the electrodes from the heart surface. Electrocardiographic Imaging 
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(ECGI) is a novel imaging technique that greatly improves upon the resolution of the standard 
12-lead ECG. ECGI is performed by solving the inverse problem in electrocardiography. 
1.2.1 Theoretical Background 
The inverse problem is governed by Laplace’s equation (∇2Φ = 0) and boundary equations on 
the heart and torso surfaces 3. In plain terms, Laplace’s equation describes the relationship 
between voltages on an inner surface (the heart) and an outer surface (the torso). Laplace’s 
equation can be applied to the heart-torso geometry when there are no electrical sources between 
the heart and torso surfaces. When Laplace’s equation holds, it is possible to apply boundary 
conditions to calculate the value of the voltage on one of the surfaces when the position of the 
inner surface relative to the outer surface is known. Solutions to Laplace’s equation for arbitrary 
geometries can be formulated by discretizing the inner and outer surfaces and solving the 
equation with the Boundary Element Method 4. Therefore, applying Laplace’s equation the heart 
requires the position of the heart relative to the torso surface and knowledge of the boundary 
conditions. 
The first boundary condition applied to Laplace’s equation in ECGI states that the normal 
derivative of voltage is zero at the torso surface. This condition holds because the air surrounding 
the torso is an insulating medium that does not support current flow out of the body. The second 
boundary condition is that the voltage on the heart surface is known. Applying these conditions 
and solving for the voltage on the torso-surface is known as the forward problem in 
electrocardiography. However, ECGI is concerned with the inverse problem in 
electrocardiography. To solve for the inverse problem, the terms of the forward problem are 
rearranged to formulate an equation for the voltage on the surface of the heart as a function of the 
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voltage on the torso surface, which can be easily measured non-invasively. While a unique 
solution to the inverse problem exists, the inverse problem is “ill-posed.” 
The term ill-posed means that small inaccuracies in the measurements of the input values may 
produce very large errors in the output. Sources of inaccuracy in the electrocardiographic inverse 
problem include noise in voltage measurements and small inaccuracies introduced by 
representing the heart-torso geometry using discretized surfaces. Because these sources of noise 
are unavoidable, regularization is employed to stabilize the solutions to the inverse problem. The 
term regularization broadly encompasses various strategies that have been developed to stabilize 
the solutions to ill-posed problems 5-10. 
1.2.2 Methodology 
ECGI is performed by combining ECG recordings from the torso of patients with non-invasive 
imaging of the heart-torso geometry, then computing voltages on the heart by applying 
regularization to the inverse problem. A schematic of the procedure is presented in Figure 1.1. 
Approximately 250 ECGs are simultaneously recorded from the torso-surface. After the 
recordings are obtained, patients are imaged using a computed tomography (CT) or magnetic 
resonance imaging (MRI) scan to obtain images of the heart-torso geometry. A novel 
contribution of this thesis was a modification of the imaging protocol to enable compatibility 
with MRI. Compatibility is achieved by removing the electrode strips, which cannot be safely 
worn in the magnetic field of an MRI scanner, and replacing them with MRI-visible marker 
strips. This process is depicted in Figure 1.2. A major benefit of this modification is that it 
avoids exposing patients to the ionizing radiation of a CT scan. 
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Figure 1.1 Schematic of the ECGI procedure. Body-surface potentials are recorded from the torso surface using a 
portable recording system (top). The heart-torso geometry is obtained using a computed tomography (CT) or 
magnetic resonance imaging (MRI) scan (bottom). The heart-torso geometry and torso potentials are combined and 
the inverse problem is solved to reconstruct unipolar epicardial electrograms. Electrograms are processed to 
determine local electrical parameters of interest (right frame). 
 
1.2.3 Validation 
The methodology of ECGI has been developed and extensively validated over multiple decades. 
The technique was first validated using tank-torso studies. In these studies, animal hearts were 
suspended in a human torso-shaped tank, and reconstructed voltages on the heart surface 
(referred to as electrograms) were validated using directly-measured values 11. ECGI 
reconstructions were also validated in humans by comparing reconstructed electrograms to direct 
intraoperative mapping recordings 12. After many years of incremental improvements to the 
technique and validation, the current implementation has been successfully applied to many 
studies of human arrhythmia 13-15. 
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Figure 1.2 Modification to the Electrocardiographic Imaging (ECGI) procedure for MRI compatibility. Recording 
electrodes (left) cannot be safely worn in the magnetic field of an MRI scanner. The electrodes are removed and 
replaced with strips of MRI-visible markers (middle). The resulting images reveal the position of the electrodes 
relative to the heart surface (right), which is necessary for the ECGI reconstruction. 
 
1.3 Dissertation Organization  
Chapters 2 and 3 of this thesis describe novel applications of ECGI. In each case, ECGI is 
combined with additional noninvasive imaging techniques to study clinically important diseases. 
A common thread of each of these studies, and a significant contribution of this thesis, is a 
population of healthy adult controls. As ECGI is applied to additional forms of heart disease, a 
control group of healthy adults is increasingly important. In each of the co-authored chapters that 
follow, my role was to serve as the individual primarily responsible for data collection, analysis, 
and manuscript preparation. The motivation and experimental techniques applied in Chapters 2 
and 3 are described below. Chapter 4 concludes this thesis with remarks about the overall 
contributions of these research efforts and future research directions that can build on the work 
presented here. 
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1.4 Overview of Chapter 2 
1.4.1 Study Design 
Chapter 2 is an investigation of ECGI and structural imaging in 20 patients diagnosed with 
arrhythmogenic right ventricular cardiomyopathy (ARVC). This study was performed in 
collaboration with researchers at University College London. In this study, ARVC patients were 
imaged with ECGI and late gadolinium enhancement (LGE) MRI. Patients in this study also 
exercised using a supine bicycle. In many patients the exercise induced premature ventricular 
contractions (PVCs), which are potential triggers of arrhythmia. We mapped the location of the 
PVCs using ECGI and related the PVCs to structural and electrical abnormalities. 
1.4.2 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
ARVC is a major cause of sudden death in young individuals and has a prevalence estimated as 
high as 1 in 1000 16. The disease was originally called arrhythmogenic right ventricular dysplasia 
(ARVD) because it was thought to be caused by a congenital defect in the right ventricle. 
However, we now know the disease is caused by genetic defects in desmosomes, which are the 
structures that connect cardiomyocytes 17. Desmosomal mutations progressively cause the 
distinctive feature of ARVC, which is a loss of healthy heart muscle (myocardium) and 
replacement by fibrous and fatty tissue 17. This progressive process of fibrofatty tissue 
replacement is thought to cause abnormal conduction of the electrical signal for contraction, 
which can lead to dangerous arrhythmias. The risk of sudden death in patients with ARVC may 
be increased by sports activity. The rarity and progressive nature of ARVC make diagnosis and 
risk stratification extremely difficult. In many cases, the first manifestation of ARVC is sudden 
cardiac death. The only treatment proven to prevent sudden death is implantable cardioverter 
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defibrillator (ICD) implantation, however, implantation carries risks and primary prevention 
indications remain a matter of debate 18,19. Because the key feature of ARVC is fibrofatty tissue 
replacement, structural imaging techniques appear well-suited to for application to ARVC. 
However, the regions of scar in ARVC may be small and diffuse, making them difficult to detect 
with conventional imaging techniques. There is also evidence that the earliest signs of the 
disease are electrical abnormalities. 
1.4.3 Late Gadolinium Enhancement 
Late gadolinium enhancement (LGE) is an imaging technique that can detect evidence of 
structural scar in the heart 20. LGE imaging is performed by injecting patients with an MRI-
visible contrast agent. Regions of tissue with increased extracellular space (e.g., regions of 
cardiac scar) accumulate more of the contrast agent and appear brighter when imaged 21. 
1.4.4 Key Findings 
We found abnormal conduction and repolarization in ARVC patients compared to controls. 
These abnormalities spatially co-localized with structural scar imaged with LGE. The majority of 
patients had PVCs, which generally increased in frequency during exercise. The PVCs originated 
in regions of electrical abnormalities and structural scar, making these regions a good target for 
clinical intervention. ECGI detected conduction abnormalities in a young patient with ARVC 
who had no other physical symptoms and no visible scar in LGE. 
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1.5 Overview of Chapter 3 
1.5.1 Study Design 
Chapter 3 is a prospective longitudinal study of heart failure in 30 patients undergoing cardiac 
resynchronization therapy (CRT). Patients were imaged using ECGI and speckle-tracking 
echocardiography (STE) prior to treatment, which allowed us to test how well the imaging 
techniques were able to predict favorable response to treatment. We performed repeat imaging 
after 3 and 6 months of treatment to observe how the heart physiology changes in response to 
CRT. In addition to performing ECGI and STE in a control group of 20 healthy patients, we 
performed tagged MRI on the controls. 
1.5.2 Heart Failure and Cardiac Resynchronization Therapy (CRT) 
In contrast to ARVC, which is relatively rare, heart failure is highly prevalent. An estimated 6.5 
million American adults have heart failure, and this number is projected to grow to more than 8 
million by 2030 1. While the 5-year fatality rate after hospitalization for heart failure is still very 
high at 42.3%, it represents a substantial improvement thanks to continued advances in treatment 
1. One of the most significant advances in the treatment of heart failure is cardiac 
resynchronization therapy (CRT). CRT is a pacemaker-based treatment that is designed to 
improve the synchrony of contractions in the heart. Approximately 30% of heart failure patients 
have regions of delayed electrical depolarization in their ventricles 22. The result of this delay is 
that the contractions of the ventricles are not synchronized and do not pump blood as efficiently 
as normal, synchronized contractions. This electrical delay manifests in the portion of the ECG 
representing ventricular depolarization (known as the QRS complex) being wider than normal. 
CRT is effective at correcting some of this dyssynchrony by pacing the heart at multiple 
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locations to resynchronize contractions. Large-scale clinical trials have shown that CRT 
improves patient quality of life, reduces heart failure related hospitalizations, and prolongs 
patient survival 23-26. While CRT has revolutionized treatment, it has been plagued by a 
remarkably stable rate of about 30% of patients who do not respond to the treatment. Because the 
dyssynchronous contraction in these patients is ultimately a mechanical phenomenon, there has 
been debate over whether mechanical imaging techniques can measure the dyssynchronous 
contractions and provide better patient selection criteria than the current ECG-based techniques. 
1.5.3 Speckle-Tracking Echocardiography 
Speckle-tracking echocardiography (STE) is an ultrasound-based imaging technique for 
measuring strain. Strain is a mechanical property defined as a change in a material’s length 
divided by its original length. Strain is useful in cardiology as a measure of the contraction of 
heart muscle. Negative strain values indicate that the muscle contracted, while positive values 
indicate that it stretched. STE measures strain in cardiac ultrasound images by tracking 
characteristic speckled patterns that appear in these images and measuring the distances between 
those patterns. STE is most commonly performed in 2D views of the heart. Key advantages of 
STE include its high framerate and its safety in patients with implanted metal devices such as 
pacemakers. 
1.5.4 Tagged MRI 
Tagged MRI is an MRI-based technique for imaging strain and is considered a gold standard for 
measuring strain. Tagged MRI works by creating grid-shaped patterns in images of the heart, 
then tracking the motion of the grids over time. Key advantages of tagged MRI over STE are that 
11 
 
it provides full 3D strain in the entire left ventricle and that the grid features are not affected by 
their motion relative to the imaging plane. 
1.5.5 Key Findings 
The most effective predictor of response to CRT was the ventricular dyssynchrony measured 
with ECGI. The time of peak contraction measured by STE did not accurately reflect the 
electrical activation sequence, indicating that the strain curves are affected by other mechanical 
factors such as opposing wall contractions and do not always reflect the sequence of electrical 
activation. CRT caused beneficial improvements in contraction that persist even when pacing is 
disabled. CRT also caused prolonged repolarization in the area of the left ventricular pacing lead, 
which may increase the risk of arrhythmia in these patients. 
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2.1 Abstract 
Background:  Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a significant cause 
of sudden cardiac death in the young. Improved noninvasive assessment of ARVC and better 
understanding of the disease substrate are important for improving patient outcomes. 
Methods and Results:  We studied 20 genotyped ARVC patients with a broad spectrum of 
disease using Electrocardiographic Imaging (ECGI; a method for noninvasive cardiac 
electrophysiology (EP) mapping) and advanced late gadolinium enhancement (LGE) cardiac 
magnetic resonance scar imaging.  Compared to 20 healthy controls, ARVC patients had longer 
ventricular activation duration (median 52 vs 42 ms; p = 0.007) and prolonged mean epicardial 
activation-recovery intervals (a surrogate for local action potential duration; median 275 vs 241 
ms; p = 0.014). In these patients, we observed abnormal and varied epicardial activation 
breakthrough locations, and regions of non-uniform conduction and fractionated electrograms. 
Non-uniform conduction and fractionated electrograms were present in the early concealed phase 
of ARVC. EP abnormalities co-localized with LGE scar, indicating a relationship with structural 
disease. Premature ventricular contractions (PVCs) were common in ARVC patients with 
variable initiation sites in both ventricles. PVC rate increased with exercise, and within 
anatomical segments it correlated with prolonged repolarization, electrical markers of scar, and 
LGE (all p < 0.001). 
Conclusions: ECGI reveals EP substrate properties that differ in ARVC patients compared to 
healthy controls. A novel mechanistic finding is the presence of repolarization abnormalities in 
regions where ventricular ectopy originates. The results suggest a potential role for ECGI and 
LGE in early diagnosis and non-invasive follow-up of ARVC patients. 
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2.2 Introduction 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) [abbreviations are defined in 
Supplemental Table S2.1] is an important hereditary cause of sudden cardiac death in young 
individuals with an estimated prevalence as high as 1:1000 1,2. The ARVC phenotype is 
progressive, consisting of an early concealed phase, overt arrhythmias, and heart failure. 
However, penetrance is variable and the first manifestation of the disease may be sudden cardiac 
death 1,2. Diagnosis and treatment of ARVC are challenging, with implications for family 
screening and risk stratification 3,4.  
ARVC is characterized by fibro-fatty infiltration of the myocardium with an epicardial 
predominance, suggesting that the disease progresses from epicardium to endocardium 5. Fibro-
fatty replacement in ARVC results from desmosomal mutations that lead to progressive 
cardiomyocyte death 6. The desmosomal mutations cause decreased function of sodium channels 
and gap junctions in cardiomyocytes 6,7. Exercise hastens disease progression by elevating 
myocardial wall stress, especially in the right ventricle (RV) 8, and has been linked to episodes of 
sudden cardiac death. Human and murine studies demonstrated that electrophysiological changes 
precede the structural disease 9. Though originally described as a RV disease, there is increasing 
evidence for non-classical presentation with both biventricular and left ventricular (LV)-
dominant disease 10. 
Definitive diagnosis of ARVC requires histological demonstration of fibrofatty replacement of 
myocardium or the presence of a known ARVC genotype. Biopsy is challenging because the 
fibro-fatty infiltration may be patchy and epicardial. Genotypes linked to ARVC are present in 
only 30-40% of cases. Current diagnosis utilizes a combination of structural, functional, and 
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electrophysiological (EP) criteria 3. However, diagnosis is challenging because of the progressive 
nature of ARVC and its early concealed phase. The only treatment proven to prevent sudden 
cardiac death in ARVC patients is the implantable cardioverter defibrillator (ICD). However, 
ICD implantation carries risks, and primary prevention indications remain a matter of debate 4,11. 
Effective non-invasive modalities and improved understanding of ARVC arrhythmia 
mechanisms are essential for accurate diagnosis and risk stratification. As stated in a recent 
editorial, access to the epicardium for electrical measurements can enhance earlier disease 
detection. However, direct epicardial access is challenging and limited to experienced clinical 
centers 12. The present study employs a noninvasive method (Electrocardiographic Imaging: 
ECGI; also referred to as Electrocardiographic Mapping (ECM) or body-surface mapping) 13 for 
epicardial EP mapping and the latest generation of magnetic resonance imaging (MRI) for 
cardiac structure (cardiac MRI (CMR) with advanced late gadolinium enhancement (LGE) using 
motion correction reconstruction) 14. We applied ECGI and LGE to study the electrical and 
structural substrates in ARVC patients. These two techniques are safe, noninvasive, and well 
suited to longitudinal assessment of ARVC patients. The goal of this study is to provide insight 
into the myocardial substrate and arrhythmia mechanisms in ARVC. It also constitutes a 
preliminary exploration of the suitability of combined ECGI and LGE for diagnosis and risk 
stratification of ARVC patients. 
2.3 Methods 
2.3.1 Patient Cohort 
Twenty ARVC patients with a broad spectrum of structural and electrophysiological disease 
were enrolled at the Heart Hospital, UCLH, London, UK. All patients were genotyped for 
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desmosomal mutations. Patient characteristics are summarized in Table 2.1 (additional clinical 
characteristics provided in Supplemental Tables S2.2 and S2.3). The study was approved by 
the National Research Ethics Service Committee London (14/LO/0360) and the Human Research 
Protection Office at Washington University in St. Louis. All patients provided written informed 
consent. The study conformed to the declaration of Helsinki. 
 
Table 2.1 
Patient ID Age Gender Mutation Major Criteria Minor Criteria 
1 59 M JUP 1 1 
2 63 M PKP2 1 3 
3 54 F PKP2 2 3 
4 44 M DSP 1 3 
5 55 M DSP 1 5 
6 63 M PKP2 3 3 
7 59 M DSP 1 3 
8 69 F PKP2 0 2 
9 61 M DSP 1 2 
10 41 F DSP* 1 1 
11 49 F PKP2 3 2 
12 60 M DSG 3 2 
13 26 M PKP2 0 3 
14 66 M PKP2 2 1 
15 54 M PKP2 2 0 
16 74 M DSG 1 3 
17 24 M DSP 1 0 
18 54 M Negative 2 2 
19 39 M Negative 2 2 
20 75 M Negative 2 3 
 
ARVC patient characteristics including Task Force Major and Minor Criteria (numbers indicate how many Major and 
Minor Criteria were observed). Mutation abbreviations: Plakoglobin (JUP), Plakophilin-2 (PKP2), Desmoplakin 
(DSP), Desmoglein (DSG). Asterisk indicates variant of unknown significance.  
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2.3.2 ECGI and MRI  
The ECGI method was developed and validated in our laboratory and described previously 13. A 
schematic of the procedure is presented in Supplemental Figure S2.1. Briefly, 256 uniformly 
distributed body-surface electrocardiograms (ECGs) were recorded simultaneously using a 
portable recording system (ActiveTwo, BioSemi, Netherlands). Patients exercised on a supine 
ergometer for two minutes, followed by a ramp protocol of fifteen Watts/minute to a maximum 
heart rate (HR) of 120 beats/minute. Recordings were performed in the supine position at rest, 
during exercise, and immediately following exercise cessation. ECGI data were transferred to the 
Rudy lab for data processing, map construction, and analysis. 
Following the recording protocol, CMR was performed in a 1.5 T scanner (Magnetom Avanto, 
Siemens Medical Solutions, Germany). Prior to the scan, recording electrodes were replaced 
with MRI-visible markers so the electrode positions could be obtained in the same coordinate 
system as the heart geometry. A navigated anatomical sequence was used so the ECGI electrical 
and anatomical data could be merged. Conventional cine imaging and advanced LGE imaging 
were conducted following the thorax scan. The contrast agent was 0.1mmol/Kg of Gadoterate 
meglumine (Dotarem, Guerbet S.A., Paris, France) with LGE images acquired 5-15 minutes 
post-contrast. The LGE sequence was a single shot steady state free precession phase sensitive 
inversion recovery sequence 14 with motion corrected averaging and high resolution (typical 
matrix: 144 x 256; voxel size 2.0 x 1.5 x 6.0 mm3). Two patients declined contrast injection. 
Unipolar epicardial electrograms (EGMs) were reconstructed using previously described 
methods 13 (additional ECGI methodology references in Supplement). Briefly, the heart-torso 
geometry obtained from the MRI was used to compute a transfer matrix relating epicardial 
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potentials to torso potentials. The inverse problem was solved to compute epicardial EGMs from 
the recorded ECGs. Typically, 1000 EGMs were computed over the entire ventricular 
epicardium. EGMs over the valve plane were excluded from analysis. Epicardial activation and 
repolarization maps were constructed from the EGMs. ECGI reconstructions of sinus rhythm 
were computed for each patient at resting HR prior to exercise and at elevated HR immediately 
after exercise cessation. Additionally, the epicardial activation sequence was computed for each 
unique premature ventricular contraction (PVC) morphology observed. 
2.3.3 Analysis 
Segmentation 
ECGI maps and LGE images for each patient’s ventricles were divided into basal, mid, and 
apical regions. Basal and mid regions were further subdivided into anterior, anterolateral, 
inferolateral, and inferior regions. Apical regions were subdivided into anterior and inferior 
regions. EGM measures for each region were computed as the mean value from all EGMs within 
the region. 
CMR Analysis 
CMR analysis was performed using CVI42 software (Circle Cardiovascular Imaging 
Inc.,Version 5.1.2[303], Calgary, Canada). For the analysis of LGE in the LV, epicardial and 
endocardial borders were manually drawn on the short axis slices and the anterior RV insertion 
point was identified. The Otsu semi-automated technique was used to quantify LGE and was 
displayed on a bullseye plot as relative enhanced area (percentage) per segment on the 16-
segment American Heart Association model. 
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For the analysis of the RV LGE, a segmentation model was created using short axis images. 
Basal, mid and apical segments were identified using the papillary muscles as markers and 
divided into anterior, anterolateral, inferolateral and inferior segments for the basal and mid RV 
segments and as apical anterior and apical inferior segments for the RV apical segments.  
The amount of RV LGE was quantified visually as 0 (no LGE), 1 (some LGE), or 2 (high LGE) 
independently by 2 operators with 3 years of experience in CMR each (SR and HB). The 
operators’ RV LGE quantification differed initially in 2 segments. Following additional analysis 
of these segments, the reviewers reached a consensus. Analyses of the ECGI and CMR data were 
conducted independently with investigators blinded to the results of the other modality. 
Electrogram Analysis 
Reconstructed unipolar epicardial EGMs were processed to compute local electrical measures. 
Activation times (ATs) were computed as the time of steepest negative time-derivative of 
voltage (-dV/dtmax) in the local QRS complex. Recovery times (RTs) were computed as the time 
of steepest positive time-derivative (dV/dtmax) during the T-wave 15. Activation-recovery 
intervals (ARIs, a surrogate for local action potential duration) were computed as the difference 
between RT and AT. Supplemental Figure S2.2 defines these measures. ECGI-reconstructed 
ARI values were validated against direct intraoperative epicardial mapping in humans (Zhang et 
al. Online Supplement 16). Spatial gradient magnitudes of EGM measures were computed for 
each EGM as the absolute value of the change between neighboring EGMs divided by the 
distance between EGM locations, averaged across all neighbors. EGM amplitudes were 
computed as the peak-to-peak voltage during the QRS complex. Fractionation was quantified 
using the number of steep downward deflections between QRS onset and the start of the T-wave. 
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Additional details of the fractionation quantification and sample EGMs are provided in 
Supplemental Figure S2.3. The earliest 10% of ATs were considered the epicardial initiation 
site of a PVC. PVC occurrence rates per EGM at a given epicardial site were computed as the 
number of times the EGM met the above criterion divided by the total number of beats recorded 
during the study. 
Statistical Analysis 
Fractionation values within anatomical segments are presented as z-scores compared to a group 
of 20 healthy adults. Electrical measures in the ARVC study population were compared to 
healthy controls using Wilcoxon rank-sum tests. Exercise changes were assessed using Wilcoxon 
signed-rank tests. Cohort data are presented as medians and quartiles. Substrate and PVC rate 
comparisons were performed using Spearman correlation coefficients computed using Matlab 
software (The MathWorks, Inc., Natick, Massachusetts, USA). 
2.4 Results 
2.4.1 Electrical Substrate at Rest 
Abnormal sinus rhythm activation and conduction were common in the ARVC patients. The 
normal epicardial activation pattern is well described 17 and a representative control is presented 
in Figure 2.1. Generally, the earliest epicardial activation appears as a breakthrough, most 
commonly in the anterior RV, and the basal lateral LV is usually the latest region to activate (Fig 
2.1A). The normal sinus activation of healthy adult hearts does not have regions of discontinuous 
conduction or fractionated EGMs (Fig 2.1A and 2.1B, left). In contrast to the normal activation 
sequence, we observed abnormal and varied epicardial breakthrough locations, regions of 
discontinuous conduction, and fractionated electrograms in the ARVC study population.  
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Figure 2.1 Electrical substrate in a healthy adult. (A) Sinus rhythm activation with a typical RV epicardial 
breakthrough (asterisk) and normal conduction. RV (1) and LV (2) unipolar EGMs have a normal morphology free 
of fractionation. (B) Schematic maps of normal electrical properties in anatomical regions based on 20 control 
subjects. Left: fractionation z-score.  Right: Fridericia-corrected ARI. The maps show absence of fractionation and 
ARI values within the normal range. AT: activation time. RA: right atrium. LA: left atrium. RV: right ventricle. LV: 
left ventricle. ARI: activation-recovery interval. EGM: electrogram. 
 
Figures 2.2-4 present activation and conduction patterns seen in ARVC patients. In two patients 
with advanced disease (63 and 66 years old, respectively) we observed earliest epicardial 
breakthrough in the LV (Fig 2.2A and 2.3A). One of these patients had normal epicardial EGMs 
(Fig 2.2A), while we observed low-amplitude fractionated EGMs in the other (Fig 2.3A). ECGI 
resolved activation and conduction abnormalities in a 26-year-old patient who did not have any 
Major Task Force Diagnostic Criteria. In this patient, we observed fractionated EGMs and non-
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uniform conduction near the earliest epicardial breakthrough site (Fig 2.4A). ARVC patients had 
fractionation scores within anatomical regions that ranged from values within the control range 
(Fig 2.2B, top) to values which were several standard deviations above the control distribution 
(Fig 2.3B and 2.4B, top). While some patients had high fractionation scores, we did not observe 
EGMs in these patients with deflections after the QRS complex (late potentials) that are 
commonly associated with re-entrant arrhythmias (Fig 2.2A-4A). The abnormal conduction in 
ARVC patients compared to controls was reflected in statistically longer total duration of 
epicardial activation (p = 0.007, Control: 42 [36-47] ms, ARVC: 52 [44-64] ms) and steeper 
mean epicardial gradients of AT (p = 0.018, Control: 0.24 [0.21-0.28] ms/mm, ARVC: 0.31 
[0.26-0.37] ms/mm). 
Repolarization in ARVC patients was prolonged compared to controls, and this prolongation was 
often spatially heterogeneous. Figure 2.1B (right) presents a schematic map of mean ARI values 
in epicardial segments for a representative control. Control values were homogenous and fell 
within the range of values previously reported 17. In contrast, Figures 2.2B and 2.3B (middle) 
show prolonged ARI values in ARVC patients. As demonstrated in Figure 2.2B (top), regions of 
normal ARI values may co-exist with regions of long ARIs. Mean ventricular ARIs during 
resting sinus rhythm (Fridericia rate correction applied) were significantly longer than control 
values (p = 0.014, Control: 241 [230-262] ms, ARVC: 275 [238-300] ms). While ARIs were 
prolonged in ARVC patients, we did not observe increased spatial gradients of repolarization or 
total duration of epicardial repolarization (Supplemental Table S2.4). 
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Figure 2.2 Electrical substrate of a patient (Patient 6) with advanced disease and a high PVC rate (18.69%). (A) 
Ventricular epicardial breakthrough during sinus rhythm was abnormal, with earliest activation originating from the 
basal inferior LV (asterisk). RV (1) and LV (2) unipolar EGMs had normal QRS morphology. (B) EGM 
fractionation was not abnormal compared to controls (top). Fridericia-corrected ARIs were prolonged compared to 
control values (middle). Concentrated LGE was visible in the inferior RV (bottom). (C) MRI image of extensive 
LGE, which was confined to the subepicardial RV (indicated by yellow arrows). PVC: premature ventricular 
contraction. 
The presence of T-wave inversion on clinical ECG (clinical ECG findings in Supplemental 
Table S2.2) was strongly associated with ARI prolongation. ARVC patients with T-wave 
inversion (Fridericia rate correction applied) had significantly longer mean ARI values than 
those without inversion (p = 0.010, With Inversion: 300 [269-313] ms, Without Inversion: 238 
[231-262] ms). However, ECGI identified a patient without T-wave inversion whose mean 
epicardial ARI was longer than any control, as well as a patient with T-wave inversion whose 
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mean epicardial ARI was within the lowest quartile of the control values (Supplemental Table 
S2.5). 
As expected, mean epicardial ARI (uncorrected for HR) shortened due to exercise (p < 0.001). 
Total RT (p = 0.002), mean epicardial RT gradients (p = 0.007), and mean EGM amplitude (p < 
0.001) also decreased due to exercise. Total AT, mean epicardial AT gradients, and fractionation 
were unaffected by exercise (Supplemental Table S2.6). 
 
Figure 2.3 Electrical substrate of a patient (Patient 14) with biventricular disease and a moderate PVC rate (1.11%). 
(A) Sinus rhythm breakthrough was abnormal, with earliest epicardial activation originating from the basal lateral 
LV (asterisk). RV (1) and LV (2) unipolar EGMs were fractionated (note the voltage scale of low-amplitude EGM 
1). (B) Regions of high fractionation were present in both ventricles (top), and Fridericia-corrected ARI values were 
prolonged compared to control values (middle). LGE was visible in both ventricles (bottom). (C) MRI image of 
LGE showing scar in both ventricles (yellow arrows).2.4.2 Electrical Substrate during Stress 
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Figure 2.4 Electrical substrate of a 26-year-old male (Patient 13) with early disease and no observed PVCs. (A) 
Sinus rhythm epicardial breakthrough occurred in the inferolateral RV (asterisk in inset) with early activation of the 
RV free wall. There was a region of non-uniform conduction and fractionated unipolar EGMs (1) between these 
sites. Remote LV unipolar EGM (2) had a normal morphology. (B) Fractionation in the RV was much greater than 
control values (top) while Fridericia-corrected ARI values were within the normal range of controls (middle). 
Minimal LGE was visible in the LV (bottom). (C) MRI showed minimal abnormalities (arrow). 
 
2.4.3 Structural (CMR) Substrate 
Advanced LGE revealed a spectrum of scar burden in the ARVC patients. There was scar in 72% 
of ARVC patients agreeable to contrast. Three patients had isolated RV LGE, seven had isolated 
LV LGE, three had biventricular LGE, and five had no scar. Six patients in the study cohort had 
no Task Force CMR defects. Of these six, three had visible LV LGE. Panels B (bottom) and C 
of Figures 2.2-4 illustrate the broad spectrum of LGE observed in the study population. 
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2.4.4 Relationship of Electrical and Structural Substrates 
LGE scar spatially co-localized with EP substrate abnormalities, and the relationship between 
CMR scar and EP abnormalities was stronger in the LV than in the RV. The amount of LV LGE 
within anatomical segments correlated with EGM markers of abnormal depolarization including 
low amplitude EGMs, increased number of deflections per EGM, and increased AT spatial 
gradients. LV LGE correlated with prolonged resting ARI values and increase in ARI shortening 
during and post exercise (Supplemental Table S2.7). RV LGE values within anatomical 
segments did not correlate with EGM markers of abnormal depolarization, but did correlate with 
prolonged ARIs at rest and post-exercise. RV LGE correlated with ARI shortening due to 
exercise (Supplemental Table S2.8). 
The results from Patient 6 (Fig 2.2) and Patient 14 (Fig 2.3) illustrate the above findings. Patient 
6 has an RV anatomical scar that does not extend to the epicardium, as determined from LGE 
(Fig 2.2C). The absence of scar on the epicardium is reflected in the local EGMs (EGM 1, Fig 
2.2A), which appear normal. This is also reflected in the normal fractionation z-scores (Fig 2.2B, 
top). Patient 14 has a similar RV anatomical scar, which lacks clear epicardial involvement (Fig 
2.3C). However, in this case, the ECGI reconstructed epicardial EGMs at this location (EGM 1, 
Fig 2.3A) are low amplitude and fractionated, indicating EP abnormality at the epicardium. The 
same patient also has an LV scar which is visible on the epicardial aspect of the lateral LV. For 
this scar, the corresponding epicardial EGMs (EGM 2, Fig 2.3A) are fractionated, indicating 
coexistence of abnormal anatomical and EP substrates on the epicardium. 
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2.4.5 Ventricular Ectopy 
Ventricular ectopy was common in the ARVC patients and occurred more frequently as heart 
rate increased following exercise. We observed PVCs in fifteen of twenty ARVC patients, with a 
total of 41 distinct morphologies. The sites of earliest epicardial activation of the PVCs were 
spread across both ventricles, with greater involvement of RV and basal locations. A schematic 
diagram of the earliest epicardial activation sites for all PVC morphologies is provided in Figure 
2.5. 
 
Figure 2.5 Schematic diagram of earliest epicardial activation of all observed PVC morphologies. Each marker 
represents a unique PVC morphology, with the number indicating the number of times the morphology was 
observed during the study. Marker color and shape identify patient ID (indicated below diagram). Sites near the 
epicardial aspect of the septum are shown on the edge of the RV. 
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Figure 2.6 PVC onset and initiation sites of a patient (Patient 6) with a high PVC burden (18.69%). (A) Time-
course of observed PVCs in relation to exercise and schematic map of PVC initiation sites. The different PVC 
initiation sites are labeled A, B, and C and color coded. PVCs occurred only after the onset of exercise, and 
morphology C appeared only once near peak HR (B) Activation isochrone maps of the three distinct PVC 
morphologies observed in this patient. Asterisks indicate PVC initiation sites. Morphology B showed very a broad 
region of early epicardial activation, indicating a possible sub-epicardial origin and possible conduction system 
involvement. HR: heart rate. 
The PVC rate within anatomical segments correlated with prolonged ARIs, ARI shortening due 
to exercise, low voltage EGMs, increased deflections per EGM, and LGE scar (all correlations p 
< 0.001). The PVC rate within anatomical segments did not correlate with increased gradients in 
AT, RT, or ARI. Figures 2.6 and 2.7 show the temporal occurrence and spatial location and 
propagation of PVCs in two patients. The substrates for these patients are presented in Figures 
2.2 and 2.3, respectively. Supplemental Table S2.9 summarizes the correlations between PVC 
rate and structural and EP substrate measures. 
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Figure 2.7 PVC onset and initiation sites of a patient (Patient 14) with a moderate PVC burden (1.11%). (A) Time-
course of observed PVCs in relation to exercise and schematic map of PVC initiation sites. Note that morphology C 
is partially obscured in the post-exercise recording period. (B) Activation isochrone maps of the three distinct PVC 
morphologies observed in this patient. Asterisks indicate PVC initiation sites. 
2.5 Discussion 
This is the first evaluation of ECGI in ARVC patients. ECGI was sensitive enough to detect EP 
substrate differences between ARVC patients and healthy controls. By combining ECGI with 
LGE, we determined correlations between EP abnormalities and LGE scar. These correlations 
indicate that the EP abnormalities detected with ECGI are markers of disease progression. 
Importantly, new findings regarding properties of the EP and scar substrates included prolonged 
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epicardial ARIs and a relationship of PVC rate within a region to repolarization, EP markers of 
scar, and LGE. 
2.5.1 ARVC Scar Substrate 
Ventricular LGE was variable in location and extent. LV LGE was a more frequent finding than 
RV LGE. LV LGE co-localized with traditional markers of EP scar assessed using ECGI, as 
reflected by its correlation with lower voltage EGMs and increased fractionation. This finding 
mirrors prior ECGI studies that found regions of scar assessed with LGE or single-photon 
emission computed tomography to have lower voltage EGMs and increased fractionation 18. In 
the RV, we did not observe a strong relationship between LGE and traditional EP markers of 
scar. This is consistent with prior work comparing invasive EP mapping to RV LGE, which 
found that nearly 50% of electrical scar substrates in the RV were not confirmed by LGE 19. 
Prior studies have suggested that the absence of RV LGE findings could be attributed to the thin 
RV wall, which complicates LGE in the RV 20. Alternatively, it is possible that EP abnormalities 
in the RV manifest in the presence of minimal scar or scar that is diffuse and not easily resolved 
with current imaging techniques.  
2.5.2 Prolongation of Repolarization 
There are multiple mechanisms which could contribute to the ARI prolongation observed in this 
study. Functional changes in ionic currents due to ARVC mutations could contribute to 
prolonged repolarization. Studies linking INa current to Plakophilin-2 mutations provided the first 
evidence that ARVC may have some features of a channelopathy 21. While the focus of research 
efforts in this area has largely been on depolarization, it is possible that repolarizing currents are 
altered as well. Kv1.5 channels localize to the intercalated disc and associate with Nav1.5 22,23, 
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and Kv1.5 function depends on N-cadherin, an intercalated disc protein 24. A mutation in KCNE2 
that inhibits trafficking of Kv1.5 to the intercalated disc causes prolonged repolarization 25. While 
we are unaware of direct evidence suggesting that this mechanism is involved in ARVC, it is an 
interesting avenue for exploration. 
Another mechanism which may contribute to prolonged repolarization is progression of the heart 
failure phenotype associated with ARVC. Heart failure is a known end-stage complication of 
ARVC 4, but systolic impairment of varying degrees can appear in either or both ventricles in the 
absence of clinical heart failure 10. Action potential prolongation is a hallmark of heart failure 
along with functional downregulation of potassium currents, slow conduction, and abnormal 
calcium homeostasis 26. It is possible that these features develop in ARVC patients either 
globally or locally as the disease progresses and surviving myocardium is subjected to increasing 
strains because of fibrofatty tissue replacement. 
Finally, myocardial uncoupling can increase the effects of any action potential duration 
prolongation mechanisms. Myocardial uncoupling facilitates gradients in repolarization by 
decreasing the electrotonic coupling between cells 27. Fibrofatty replacement acts to uncouple 
cells by decreasing the local density of excitable cells. Reduction in the number and size of gap 
junctions in the intercalated disc causes further uncoupling in ARVC, and has been reported even 
in histologically normal regions of myocardium 6. 
In our data, ARI prolongation correlated with LGE in both ventricles. This suggests that the 
uncoupling effect of the scar, altered mechanical strains in regions of scar, or both may be 
important to the development of prolonged repolarization. The uncoupling effect of ventricular 
scar could also contribute to the correlation we observed between stress-related ARI shortening 
35 
 
and LGE in both ventricles, as both rate increase and sympathetic stimulation have a greater 
effect on cardiomyocytes that are less electrically coupled. While our population size is not 
sufficient to draw conclusions about the age progression of the ARVC phenotype, we note that 
the group included two patients in their twenties, both of whom had ARI values within the 
normal range. This suggests that action potential prolongation in ARVC patients may develop as 
the overall phenotype progresses. Mean epicardial ARIs were generally longer in patients with 
precordial lead T-wave inversion. However, there were patients with and without T-wave 
inversion who were exceptions to this relationship, indicating that ECGI offers improved 
sensitivity and specificity for detecting prolonged repolarization. Additionally, ECGI provides 
spatial information about ARI prolongation, which was spatially heterogeneous in ARVC. 
2.5.3 Arrhythmia Triggers (PVCs) 
The ability of ECGI to panoramically map the whole heart in a single beat allowed us to localize 
PVCs, determine the frequency of each unique PVC morphology, and correlate ectopic 
frequency with the EP and scar substrates. The overall rate of PVCs was increased by exercise. 
We found that PVC rate within anatomical segments correlated with local ARI prolongation, 
increased ARI shortening due to exercise, low voltage EGMs, fractionated EGMs, and LGE. 
The hallmark finding of progressive scar formation in ARVC is compatible with the possibility 
of re-entrant circuit formation. Prior work demonstrated conduction slowing at elevated heart 
rates in ARVC patients 28. In the present study, we found evidence of slow conduction in the 
form of longer total activation times and steeper activation gradients relative to controls. 
However, we did not observe the dynamic conduction slowing at elevated HRs that Finlay et al. 
reported 28. This discrepancy could be attributable to the difference in HRs investigated. In the 
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present study, patients exercised to a peak HR of 120 beats/min, whereas the patients in the 
Finlay et al. study were paced at an interval just below the ventricular refractory period. 
The combination of scar, slow conduction, and prolonged repolarization could facilitate 
unidirectional block and reentrant arrhythmia. Important signatures of re-entrant arrhythmia are 
EGM fractionation and late potentials. We did not observe late potentials in the reconstructed 
EGMs. This stands in contrast to ECGI studies of post-infarction scar-related ventricular 
tachycardia, which found a high prevalence of late potentials with re-entry circuits closely 
related to the EP substrate 29. While this could indicate that re-entrant arrhythmias are less 
prevalent in ARVC, it is important to note the significant differences in the anatomy of the scars 
in each population. Post–infarction scars are often large and heterogeneous, with large islands of 
surviving myocardium, especially in the border zone. The ARVC scar substrate, on the other 
hand, accumulates gradually over time and is typically diffuse, originating from the epicardium. 
It is possible that the lower regional density of surviving myocardium in ARVC scar makes it 
difficult to resolve late potentials in EP mapping of ARVC patients. 
Focal mechanisms may cause arrhythmia triggers in ARVC patients. Focal triggered activity is 
commonly observed in isolated myocytes in the form of early afterdepolarizations or delayed 
afterdepolarizations. Early afterdepolarizatons at plateau potentials are caused by recovery and 
re-activation of ICa, with the delayed rectifier currents, IKr and IKs, playing an important role 30.  
We observed that PVC rate correlated with regions of prolonged ARI, a surrogate for local action 
potential duration, including during stress when ICa is augmented by beta-adrenergic stimulation. 
Action potential duration prolongation increases the window for ICa re-activation and early 
afterdepolarization formation. In the intact heart, electrotonic coupling between myocytes acts as 
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a current sink for depolarizing currents. Reduced coupling, caused by scar and gap junction 
abnormalities in ARVC, can increase the likelihood of focal activity by decreasing the current 
sink effect. The observed correlation between PVC rate and electrical and LGE markers of scar 
suggests that an uncoupling effect is present at PVC initiation sites. It is interesting to note that 
Myles et al. 31 found that focal activity was more common in the RV, which they attributed to 
reduced coupling in the thin RV wall compared to the LV. In our study, we found greater overall 
ectopy in the RV.  
2.5.4 Clinical Implications 
The progressive nature of ARVC and its early concealed phase complicate diagnosis and 
treatment. CMR currently plays a valuable role in the evaluation of ventricular structure and 
function. The current Task Force criteria do not include LGE, but acknowledge that it may be 
included in future revisions 3. Our data show that combined ECGI and LGE could increase the 
sensitivity for detecting substrate abnormalities in ARVC patients, including young patients with 
little or no Task Force MRI and ECG criteria. LGE and ECGI are compatible with the current 
use of CMR in the diagnosis and longitudinal assessment of ARVC. These imaging techniques 
can be performed in addition to the conventional CMR assessment to provide a thorough 
characterization of structural, functional, and EP abnormalities. In the present study, we report a 
spectrum of abnormalities using these techniques and demonstrate a relationship between the 
imaged substrates and ventricular ectopy. Since ventricular ectopy may play a causal role in 
triggering arrhythmias, combined ECGI and LGE may have a role in risk stratification. 
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2.5.5 Limitations 
This study is a first evaluation of combined ECGI and LGE in ARVC patients and, therefore, 
evaluated a relatively small group of twenty patients. Because CMR is commonly 
contraindicated in patients with implanted devices, we only recruited patients without ICDs. 
While this choice enabled us to image LGE in the study cohort, a drawback is that none of the 
patients in this study had prior episodes of ventricular tachycardia. Therefore, this study cohort is 
not well-suited for evaluating sudden cardiac death risk stratification. Further studies are 
necessary to explore this application of these techniques. The current study evaluated patients 
ranging in age from 24 to 75 years old; however, only three patients were younger than 41 years 
old. Future studies should evaluate whether this approach can detect the presence of ARVC in 
young, asymptomatic and genotype-positive individuals. Larger studies of a wide range of ages 
and genotypes are important for exploring the progression of the disease, including how the EP 
and scar substrates change over time. Prior studies demonstrated that strain imaging may be 
effective for detecting the early stages of ARVC and for risk stratification 32,33. Future studies 
could combine ECGI and strain imaging into a multi-modality approach for ARVC diagnosis 
and risk stratification. Exercise and LGE data were collected from the ARVC patients, but not 
controls. These data are needed to establish ranges for healthy controls. Additional data are 
necessary to determine the specificity of ECGI and LGE criteria for diagnosis of ARVC. 
2.5.6 Conclusion 
ECGI in combination with advanced LGE reveals a spectrum of electrical and structural 
substrate abnormalities in ARVC patients. This combination may improve sensitivity for 
detecting ARVC substrate abnormalities. These data suggest a role for combined ECGI and LGE 
in early diagnosis, non-invasive follow-up, and risk stratification of ARVC patients.  
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Chapter 2 Appendix 
Supplemental Figure S2.1: The ECGI Procedure 
 
 
Schematic diagram of the ECGI procedure. A computed tomography (CT) or magnetic resonance imaging (MRI) 
scan provides the geometry of the epicardial surface and the locations of the recording electrodes on the body 
surface in the same coordinate system (top). The body surface potential distribution is obtained from 256 
simultaneously recorded electrocardiograms (bottom). Solving the inverse problem (middle gray box) yields 
epicardial potentials and electrograms, from which activation times, recovery times, and other parameters of interest 
are derived (right frame).  
CT or MRI Scan
Images
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Supplemental Figure S2.2:  Activation Time, Recovery Time, and Activation-Recovery 
Intervals 
 
Diagram of unipolar electrogram (EGM) Activation Time (AT), Recovery Time (RT), and Activation-Recovery 
Interval (ARI). Temporal derivatives (bottom) were computed from EGMs (top). ATs were computed as the time of 
steepest negative time-derivative of voltage (-dV/dtmax) in the local QRS complex. Recovery Times were computed 
as the time of steepest positive time-derivative (dV/dtmax) during the T-wave. To eliminate noise effects from RT 
values, T-waves were lowpass-filtered using a 30 Hz Butterworth filter before determining RT. ARIs (a surrogate 
for local action potential duration) were computed as the difference between RT and AT. 
EGM: electrogram 
AT: Activation Time 
RT: Recovery Time 
ARI: Activation-Recovery Interval 
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Supplemental Figure S2.3:  Electrogram Fractionation 
 
 
Diagram of electrogram (EGM) deflections for a normal EGM (left) and a low-amplitude fractionated EGM (right, 
shown on the same scale). The normal EGM had a single deflection (left, circle) while the fractionated EGM had 3 
deflections (right, circles). Insets (large box) show fractionated EGM QRS voltage and dV/dt on enlarged scale. 
Fractionation was quantified by counting the number of steep downward deflections between the QRS onset and the 
start of the T-wave. Temporal derivatives (dV/dt, bottom) were computed from unipolar EGMs (top). Downward 
deflections were regions of EGMs with a negative dV/dt. Multiple deflections occurred when there was a positive 
dV/dt between downward deflections. The thresholds for steep downward deflections were: 
 
1) Deflection peak-to-peak voltage amplitude ≥ 10% of the EGM peak-to-peak voltage amplitude 
2) Deflection –dV/dt ≥ 70% of the EGM maximum –dV/dt 
Additionally, both values were required to be ≥ 5% of the corresponding median values for all EGMs to prevent the 
detection of noise in flat EGMs as fractionation. 
EGM: electrogram 
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Supplemental Table S2.1:  Manuscript Abbreviations 
 
Abbreviation Meaning 
ARVC Arrhythmogenic Right Ventricular Cardiomyopathy 
RV Right Ventricle 
LV Left Ventricle 
EP Electrophysiological 
ICD Implantable Cardioverter Defibrillator 
ECGI Electrocardiographic Imaging 
MRI Magnetic Resonance Imaging 
CMR Cardiac Magnetic Resonance 
LGE Late Gadolinium Enhancement 
ECG Electrocardiogram 
HR Heart Rate 
EGM Electrogram 
PVC Premature Ventricular Contraction 
AT Activation Time 
RT Recovery Time 
ARI Activation-Recovery Interval 
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Supplemental Table S2.3: Holter PVC Findings 
 
 
ID Age Gender PVC Count Monomorphic/Poloymorphic Morphology 
1 59 M 59 Monomorphic LBBB 
2 63 M 620 Polymorphic LBBB+RBBB 
3 54 F 1028 Monomorphic LBBB 
4 44 M 10 Monomorphic LBBB 
5 55 M 1000 Monomorphic LBBB 
6 63 M 2364 Monomorphic LBBB 
7 59 M 1111 Polymorphic LBBB+RBBB 
8 69 F 784 Monomorphic LBBB 
9 61 M >3000 Monomorphic LBBB 
10 41 F 56 Monomorphic LBBB 
11 49 F 642 Monomorphic LBBB 
12 60 M 681 Polymorphic LBBB+RBBB 
13 26 M 52 Monomorphic LBBB 
14 66 M 26 Monomorphic LBBB 
15 54 M 38 Monomorphic LBBB 
16 74 M 1056 Monomorphic LBBB 
17 24 M 56 Monomorphic LBBB 
18 54 M 3496 Monomorphic LBBB 
19 39 M 890 Monomorphic LBBB 
20 75 M >3000 Monomorphic LBBB 
 
 
Summary of 24-hour Holter findings from patient clinical records. 
 
LBBB: Left bundle branch block morphology 
RBBB: Right bundle branch block morphology 
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Supplemental Table S2.4:  ARVC–Control Group Comparisons 
 
Median, quartiles, and Wilcoxon rank sum comparison of ECGI EP parameters in healthy adults (Controls) and 
ARVC patients. Highlighted rows (yellow) indicate statistically significant differences between Control and ARVC 
groups. 
 
Significance levels: 
*** p < 0.001  
**   p < 0.01 
*     p < 0.05 
 
Q1: First Quartile 
Q3: Third Quartile 
  
 
 Control ARVC     
Parameter Median Q1 Q3 Median Q1 Q3 P Significance 
Total Activation Time (msec) 42 36 47 52 44 64 0.007 ** 
Total Recovery Time (msec) 134 126 152 129 120 146 0.273   
Mean Epicardial ARI (msec, Fridericia Rate-Correction) 241 230 262 275 237 300 0.014 * 
Mean Epicardial EGM Amplitude (mV) 2.28 2.00 3.03 2.58 1.69 2.96 0.735   
Mean Deflections Per-Electrogram 1.06 1.03 1.06 1.09 1.03 1.18 0.086   
Mean Epicardial Activation Time Gradient (ms/mm) 0.24 0.21 0.28 0.31 0.26 0.37 0.018 * 
Mean Epicardial Recovery Time Gradient (ms/mm) 1.06 0.95 1.22 0.93 0.85 1.05 0.060   
Mean Epicardial ARI Gradient (msec, Fridericia Rate-Correction) 1.17 1.07 1.38 1.21 1.05 1.48 1.000   
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Supplemental Table S2.5:  Mean Fridericia-Corrected Epicardial ARI (msec) in Controls 
and ARVC Patients with and without T-Wave Inversion 
 
Median, quartiles, Range, and Wilcoxon rank sum comparison of resting ARI (Fridericia rate-correction applied) in 
Controls and ARVC patients with and without T-Wave Inversion. Group difference ARVC with T-Wave Inversion 
is significantly different than controls at p < 0.001 level and ARVC without T-Wave Inversion at p < 0.01 level. 
 
Q1: First Quartile 
Q3: Third Quartile 
Min: Minimum value observed in group 
Max: Maximum value observed in group 
 
  
Controls ARVC: T-Wave Inversion ARVC: No T-Wave Inversion 
Median Q1 Q3 Min Max Median Q1 Q3 Min Max Median Q1 Q3 Min Max 
241 230 262 206 274 300 269 313 218 330 238 231 262 226 285 
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Supplemental Table S2.6:  Exercise Changes in ARVC Parameters 
 
Median, quartiles, and Wilcoxon signed-rank comparison of ECGI EP parameters in ARVC patients at Resting HR 
and Elevated HR after exercise. Highlighted rows (yellow) indicate statistically significant differences between 
Control and ARVC groups. 
 
Significance levels: 
*** p < 0.001  
**   p < 0.01 
*     p < 0.05 
 
Q1: First Quartile 
Q3: Third Quartile 
 
  
 
         
 Resting HR Elevated HR   
Parameter Median Q1 Q3 Median Q1 Q3 P Significance 
Total Activation Time (msec) 53 46 66 57 47 66 0.658   
Total Recovery Time (msec) 130 120 150 106 91 120 0.002 ** 
Mean Epicardial ARI (msec, uncorrected for HR) 275 235 313 186 173 203 < 0.001 *** 
Mean Epicardial EGM Amplitude (mV) 2.57 1.60 2.94 2.08 1.28 2.50 < 0.001 *** 
Mean Deflections Per-Electrogram 1.09 1.03 1.18 1.09 1.05 1.22 0.872   
Mean Epicardial Activation Time Gradient (ms/mm) 0.33 0.26 0.38 0.30 0.27 0.35 0.260   
Mean Epicardial Recovery Time Gradient (ms/mm) 0.94 0.87 1.06 0.70 0.60 0.88 0.007 ** 
Mean Epicardial ARI Gradient (msec, Fridericia Rate-Correction) 1.22 1.07 1.49 1.12 1.01 1.38 0.687   
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Supplemental Table S2.7:  Correlation of EP Substrate to LV Late Gadolinium 
Enhancement 
 
Spearman correlation coefficients of LV LGE and EP substrate parameters. Highlighted rows (yellow) indicate 
statistically significant correlations between LV LGE and EP substrate parameters. 
 
Significance levels: 
*** p < 0.001  
**   p < 0.01 
*     p < 0.05 
 
 
  
Parameter CC P Significance 
EGM Amplitude -0.42 < 0.001 *** 
Deflections Per-EGM 0.52 < 0.001 *** 
AT Spatial Gradient 0.24 0.001 ** 
Resting ARI 0.29 < 0.001 *** 
Exercise ARI 0.10 0.190   
RT Spatial Gradient -0.09 0.232   
ARI Spatial Gradient 0.05 0.485   
Exercise ARI Shortening 0.31 < 0.001 *** 
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Supplemental Table S2.8:  Correlation of EP Substrate to RV Late Gadolinium 
Enhancement 
 
Spearman correlation coefficients of RV LGE and EP substrate parameters. Highlighted rows (yellow) indicate 
statistically significant correlations between RV LGE and EP substrate parameters. 
 
Significance levels: 
*** p < 0.001  
**   p < 0.01 
*     p < 0.05 
  
Parameter CC P Significance 
EGM Amplitude -0.02 0.755   
Deflections Per-EGM -0.05 0.472   
AT Spatial Gradient -0.15 0.051   
Resting ARI 0.30 < 0.001 *** 
Exercise ARI 0.17 0.027 * 
RT Spatial Gradient -0.05 0.502   
ARI Spatial Gradient -0.10 0.197   
Exercise ARI Shortening 0.36 < 0.001 *** 
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Supplemental Table S2.9:  Correlation of LGE and EP Substrate with Regional Rate of 
Ventricular Ectopy 
 
Spearman correlation coefficients of PVC rate within anatomical regions and EP substrate parameters and LGE. 
Highlighted rows (yellow) indicate statistically significant correlations between PVC Rate and substrate parameters. 
 
Significance levels: 
*** p < 0.001  
**   p < 0.01 
*     p < 0.05 
  
Parameter CC P Significance 
EGM Amplitude -0.21 < 0.001 *** 
Deflections Per-EGM 0.20 < 0.001 *** 
AT Spatial Gradient 0.04 0.457   
Resting ARI 0.35 < 0.001 *** 
Exercise ARI 0.28 < 0.001 *** 
RT Spatial Gradient -0.06 0.232   
ARI Spatial Gradient 0.00 0.943   
Exercise ARI Shortening 0.30 < 0.001 *** 
LV LGE 0.50 < 0.001 *** 
RV LGE 0.35 < 0.001 *** 
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3.1 Abstract 
Background: Cardiac resynchronization therapy (CRT) is an effective treatment for heart failure 
(HF) with benefits that include reverse remodeling of the HF phenotype. Despite the success of 
CRT, the rate of nonresponders remains around 30%. Many small studies showed promising 
results applying speckle tracking echocardiography (STE) strain imaging to patient selection, but 
larger studies showed no benefits over standard criteria. Improvements to CRT require a more 
complete understanding of the physiological changes of reverse remodeling and the relationship 
between electrical and mechanical measures of synchrony. 
Methods: We imaged 20 healthy controls and imaged 30 CRT patients longitudinally using 
electrocardiographic imaging (ECGI, a method for noninvasive cardiac electrophysiology 
mapping) and STE. We computed dyssynchrony with each technique and compared their relative 
effectiveness for predicting response to CRT. We quantified CRT-induced remodeling of 
electrical and mechanical physiological parameters. We measured the electromechanical delay 
between activation and peak strain within LV segments. We additionally performed tagged MR 
imaging on the healthy controls to provide a high-resolution 3D maps of activation, contraction, 
and repolarization in healthy human hearts. 
Results: The delay between mean lateral LV and RV electrical activation time, determined with 
ECGI, was the best predictor of beneficial reduction in LV end systolic volume and 
outperformed mechanical indices (Spearman’s Rho: -0.722, p < 0.001). The mean 
electromechanical delay within anatomical segments was similar in controls and HF patients, 
however, the HF patients had greater dispersion of delay and the values were dependent on the 
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activation sequence. After 6 months of CRT, patients had increased contraction magnitudes in 
native rhythm compared to baseline pre-CRT (baseline: -8.55%, 6 months: -10.14%, p=0.008). 
CRT also prolonged native rhythm repolarization at the location of the LV pacing lead (baseline: 
280 msec, 6 months: 306 msec, p=0.002).  
Conclusions: ECGI-measured LV activation delay is an effective index for CRT patient 
selection. CRT causes persistent improvements in contractile function, but increases dispersion 
of repolarization, which could increase the risk of arrhythmias. Electromechanical delay 
dispersion and sequence-dependence indicate that the timing of peak strains in STE is influenced 
by mechanical factors such as opposing wall contractions in addition to the activation sequence. 
3.2 Introduction 
Heart failure (HF) is a progressive disease with high prevalence and high mortality that is a 
major contributor to healthcare costs 1. HF is associated with adverse remodeling of the 
ventricular myocardium that includes chamber dilatation, slow conduction, decreased myocyte 
contraction amplitudes, and prolonged action potential durations 2-5. Approximately 30% of HF 
patients have electrical dyssynchrony, apparent by a prolonged QRS duration on the ECG 6, an 
indication of dyssynchronous ventricular contraction. Prolonged QRS duration and left 
ventricular ejection fraction (LVEF) are inversely correlated, and HF patients with QRS 
prolongation have higher all-cause mortality and may have a higher incidence of sudden death 
than those with narrow QRS complexes 6. 
Cardiac resynchronization therapy (CRT) improves the synchrony of ventricular contraction by 
bi-ventricular pacing the ventricles. CRT has dramatically improved clinical outcomes for HF 
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patients with prolonged QRS durations. Large clinical trials found that CRT improves patient 
quality of life, reduces HF-related hospitalizations, prolongs patient survival, and may reduce the 
risk of sudden cardiac death 7-10. CRT may also partially correct some of the pathological 
abnormalities in HF, a process known as reverse remodeling. Animal studies found that CRT 
restored cellular action potential duration (APD) and Ca2+ transients to normal levels 11,12. 
Despite the widely reported benefits of CRT, the rate of patients who do not respond to the 
therapy has been remarkably stable at around 30% 13. 
Multiple attempts have been made to improve on patient selection criteria for CRT using various 
electrical and mechanical indices of dyssynchrony. Multiple small studies reported promising 
results applying 2D speckle tracking echocardiography (STE) to CRT patient selection. STE is 
an imaging technique which tracks the characteristic speckled patterns in echocardiographic 
images and computes deformation of the patterns to determine strain 14. Despite many promising 
initial evaluations, the multicenter PROSPECT trial found that no echocardiographic measures of 
dyssynchrony improved patient selection for CRT, and the EchoCRT trial, which evaluated CRT 
in patients with mechanical dyssynchrony and a narrow QRS complex, was stopped for futility 
with the conclusion that CRT was possibly detrimental in that patient cohort 15,16. 
The disappointing performance of STE in CRT patient selection is an indication of gaps in our 
understanding of the electromechanics of HF and CRT. A better understanding of the physiology 
underlying response and non-response to CRT may advance future attempts to improve the 
therapy. Basic science explorations of human cardiac electromechanics, such as whole-heart 
computer simulations of electromechanical activity, may also contribute to better understanding 
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of CRT. However, electromechanical data from non-diseased human hearts are currently lacking 
17. The present study combines STE with Electrocardiographic Imaging (ECGI; a noninvasive 
method for cardiac electrophysiology mapping) 18 to study the electromechanics of CRT in HF 
patients in situ. We imaged CRT patients longitudinally to determine baseline dyssynchrony, 
acute resynchronization, and reverse remodeling after 3 and 6 months of CRT pacing. We also 
collected ECGI and STE from a group of 20 healthy adult volunteers to serve as a control 
baseline for comparison. In this group, we also performed tagged MRI 19 to provide a complete 
three-dimensional data set of the normal electromechanical sequence of healthy adult hearts. 
3.3 Methods 
3.3.1 Patient Cohort 
We enrolled 20 healthy adults and 30 HF patients undergoing CRT at Washington University in 
St. Louis. Healthy volunteer demographics are provided in Supplemental Table S3.1, and HF 
characteristics are provided in Supplemental Table 3.2. The study was approved by the Human 
Research Protection Office at Washington University in St. Louis. All participants provided 
written informed consent. 
3.3.2 Electrocardiographic Imaging (ECGI) 
The ECGI method, developed and validated in our laboratory, was described previously 20. A 
schematic of the is presented in Supplemental Figure S3.1. Briefly, 256 uniformly distributed 
ECGs were simultaneously recorded from the torso using a portable recording system 
(ActiveTwo, BioSemi; The Netherlands). Patient-specific heart-torso geometries were obtained 
from CRT patients using a thoracic CT scan gated at 70% of the R-R interval while wearing the 
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recording electrodes. Heart-torso geometries of normal subjects (controls) were obtained using a 
navigated anatomic MRI sequence. In these subjects, recording electrodes were replaced with 
MRI-visible markers prior to the scan, for compatibility with MRI. The ECG recordings were 
combined with the heart-torso geometries to reconstruct unipolar epicardial electrograms 
noninvasively, using previously described methods 20. Typically, 1000 electrograms were 
computed over the entire ventricular epicardium. Electrograms over the valve plane were 
excluded from further analysis. 
3.3.3 Echocardiography 
Echocardiography was performed using a commercially available ultrasound imaging system 
(Vivid 7, GE Healthcare, Milwaukee, WI). Longitudinal strain was assessed in standard 4-
chamber, 3-chamber (apical long axis), and 2-chamber apical views. Images were obtained using 
the maximum framerate that allowed for viewing the entire left ventricle (LV) chamber, with a 
typical frame rate of 70 frames per second. Strain curves in each apical view were computed 
using vendor speckle-tracking software (EchoPAC, GE Healthcare, Milwaukee, WI). To 
minimize the effect of noise on the timing of the strain curves, 3 beats were processed for each 
view and averaged. LV volumes and ejection fractions were determined using Simpson’s biplane 
method. Volumes and ejection fractions were also determined using the averaged values of 3 
beats. In cases where the 2-chamber view could not be obtained (n = 5) the 4-chamber volume 
parameters were used. We defined echocardiographic response as a decrease in LV end systolic 
volume (LVESV) ≥ 15% and/or an increase in ejection fraction (EF) ≥ 5% at 6 month visit.  
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3.3.4 Tagged MRI 
Tagged MR images were obtained and analyzed using previously described methods 21. ECG-
gated images were obtained in short-axis and long axis views for a complete cardiac cycle 
beginning at end-diastole. Short axis slices were obtained with 8mm spacing from the level of 
the mitral valve to the LV apex. Four long-axis image sets were obtained in radially oriented 
planes. Tissue tagging was performed on each image using a Spatial Modulation of 
Magnetization radiofrequency tagging preparation, followed by 2-D balanced steady-state free 
precession cine image acquisition. Tagged and non-tagged images were acquired during the 
same breath hold to ensure similar anatomic positioning between images. Typical imaging 
parameters were described previously 21. 
The strain analysis has been described and validated 22. Epicardial and endocardial wall 
boundaries of the LV were defined in both short and long axis non-tagged images. Tag lines 
were delineated using a semi-automated active contour algorithm. The attachment points of the 
basal RV free wall were used in conjunction with a geometric model of the LV to create in finite 
element model of the LV. Strain was measured based on the deformation of the tagged surfaces 
throughout the cardiac cycle. 3D displacements were calculated from the movement of 
intramural tag surface intersection points during systole. StressCheck software (ESRD, Inc. St 
Louis, MO) was used to fit the displacement data and provide a continuous description of the 
displacement throughout the LV. Strain values in circumferential and longitudinal directions 
were calculated from this fitting. 
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3.3.5 Longitudinal CRT Studies 
The first images of CRT patients were obtained after device implant but prior to the onset of 
CRT pacing. This allowed us to determine the location of the pacing leads from the CT scan and 
image the patients prior to any CRT-induced remodeling. Patients were imaged in their native 
(un-paced) rhythm and at the onset of CRT pacing. Imaging was repeated in both paced and un-
paced rhythms after 3 and 6 months of CRT pacing. To avoid the radiation exposure of 
additional CT scans during follow-up visits, the recording electrodes were placed in the same 
locations as on the initial visit using anatomical images from the initial scan to guide electrode 
placement. 
3.3.6 Analysis 
Segmentation 
Analysis of each imaging modality was performed blinded to the results of the other modalities. 
The data were compared based on anatomical regions. The LV was segmented using a modified 
version of the American Heart Association 17-Segment Model. The standard apical segments 
were replaced with anterolateral, inferolateral, anteroseptal, and inferoseptal apical segments. For 
the ECGI analysis, the lateral right ventricle (RV)was segmented using the same convention as 
the lateral LV. Electrogram parameters for each region were computed using the mean value 
from all electrograms within the region. 
Electrogram Analysis 
Activation times were computed from electrograms as the time of steepest negative time-
derivative of voltage (-dV/dtmax). Recovery times were computed as the steepest positive time-
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derivative during the T wave (dV/dtmax) 23. Activation-recovery intervals (ARIs, a surrogate for 
local APD) were computed as the difference between recovery time and activation time. ECGI-
reconstructed ARI values have been validated against direct intraoperative epicardial mapping in 
humans (see online supplement of Zhang et al 24). Electrogram fractionation was quantified 
using the number of downward deflections between the QRS onset and T wave onset. 
Electrograms with more than 2 deflections were considered “fractionated” deflections. ARIs and 
fractionation were compared across visits in native rhythm only, to avoid the impact of altered 
activation sequence on the indices. Parameters were computed at pacing sites by averaging 
values of the 10 electrograms closest to the pacing lead locations. 
Dyssynchrony Indices 
We measured electrical dyssynchrony from the 12-lead ECG using the QRS duration. We 
defined the QRS duration as the latest QRS end in any lead minus the earliest QRS onset in any 
lead. We note that this definition differs from some measurements which report the QRS 
duration as the maximum duration in any single lead. The total activation time was defined as the 
latest epicardial activation time minus the earliest. We evaluated electrical dyssynchrony in 
ECGI using two previously reported indices. The LV activation delay was defined as the mean 
activation time in mid and basal lateral LV segments minus the mean activation time in mid and 
basal lateral RV segments 25. The LV activation dispersion was defined as the standard deviation 
of activation times within the LV 26. 
We evaluated mechanical synchrony using analogous indices applied to the echocardiographic 
strain data. The mechanical delay was defined as the mean time of peak strain in mid and basal 
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lateral LV segments minus the mean time of peak strain in mid and basal septal segments. This 
index was only computed for patients with at least two adequately-tracked segments in both the 
lateral LV and the septum. The mechanical dispersion was defined as the standard deviation of 
contraction times within the LV. This index was only computed in patients where strain data 
could be obtained in all 3 apical views. 
Temporal Alignment 
ECGI and echocardiographic parameters were aligned temporally using the body surface ECG 
from corresponding lead locations. Maxima or minima from the QRS voltage or voltage 
derivatives were used to align the ECG traces. Tagged MRI data were aligned temporally with 
the echocardiographic strain using the time of peak strain for each modality. 
Statistical Analysis 
Comparisons between controls and the HF population were performed using Wilcoxon rank-sum 
tests. Changes due to acute and chronic CRT pacing were assessed using Wilcoxon signed-rank 
tests. Correlations between parameters and volumetric reverse remodeling were performed using 
Spearman correlation coefficients. 
3.4 Results 
3.4.1 Healthy Controls 
The control population in this study was used to characterize normal sequences of activation and 
contraction, and to establish normal ranges of electromechanical parameters (medians and 
interquartile ranges of all control electrical and mechanical parameters are provided in 
Supplemental Table S3.3). The epicardial activation sequence in healthy adults is very 
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consistent in its overall pattern. In all patients, the anatomical segment of earliest activation was 
located between the lateral RV and the anterior wall in mid or basal regions. The median time 
between earliest and latest activation in controls was 42 msec, and the maximum value we 
observed in the control group was 58 msec. In all controls the LV delay parameter was greater 
than 0 (mean lateral LV activation was later than mean lateral RV activation) with a median 
value of 14 msec. The activation isochrone map of a representative control is presented in Figure 
3.1. 
 
Figure 3.1. Activation isochrones in a healthy adult. Earliest activation in healthy adults falls between the lateral 
right ventricle (RV) and anterior wall. Atria and left anterior descending coronary artery are shown in gray. Right 
ventricular outflow tract shown in blue. Left ventricular outflow tract shown in pink. LV: left ventricle; RA: right 
atrium; LA: left atrium. 
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The sequence of LV strain in controls was similarly consistent. LV segments contractions were 
highly synchronous and reached peak strain approximately 430 msec after the onset of the QRS 
complex (medians and interquartile ranges for all control parameters are provided in 
Supplemental Table S3.3). The median mechanical delay was 12 msec, though there was more 
variability than in the electrical delay parameter and several subjects had negative values (peak 
septal strain after peak lateral LV strain). The mean delay between electrical activation  and peak 
strain within anatomical segments was 375 msec. Figure 3.2 presents the contraction sequence 
and mechanical parameters for a representative control. Combining tagged MRI with ECGI 
yields high resolution 3D maps of epicardial voltage and LV displacement and strain. An 
example of the 3D electromechanical sequence is presented in Figure 3.2b, and the 
Supplemental Movie. 
Control repolarization was consistent with previous descriptions. The mean epicardial ARI value 
in the controls had a median value of 238 msec, which shows good agreement with the 
previously reported value of 235 msec 27. The larger size of the control group in this study 
compared to the prior study allowed us to measure the difference in mean epicardial ARI 
between healthy male and female adults. Males had a median of 229 msec with 19 msec 
interquartile range, and females had a median of 261 msec with 23 msec interquartile range (p = 
0.001). Representative ARI maps for a control male and a control female are presented in Figure 
3.3. 
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Figure 3.2. Healthy adult excitation and contraction. A. Speckle tracking echocardiography (STE) strain curves (top 
plot) plotted below the ECG. Electrical activation times are indicated in the plot with vertical lines (dashed lines 
indicate right ventricular activation as an approximation of septal activation time). Dotted line indicates aortic valve 
closure. The timing of peak strain within anatomical segments (top bullseye plot) was homogeneous within the LV. 
Regional electromechanical delay values (bottom bullseye plot) were computed by subtracting the electrical 
activation time from the time of peak strain within regions. B. Tagged MRI was performed on the controls, allowing 
for detailed electrical and mechanical imaging in the same coordinate system. Electrical activation is indicated as a 
transition from dark to light ventricular surface (left image). Tagged MRI displacement markers (colored dots; 
colors represent angular position within the LV) show the 3D contraction of the LV. An animation of the sequence 
is included in the Supplemental Movie. 
 
A
B
Electrical Activation Contraction Relaxation
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Figure 3.3 Activation-recovery interval (ARI) maps for a healthy adult male and female. Mean epicardial ARI 
values in female controls were approximately 30 msec longer than male controls. The longest ARI values were 
generally observed in the basal region. 
 
 
 
3.4.2 Heart Failure and Cardiac Resynchronization Therapy 
Electrical Activation 
The native (un-paced) epicardial activation sequence in HF patients was prolonged compared to 
controls (statistical comparison to controls provided in Supplemental Table S3.3, changes due 
to acute CRT pacing onset provided in Supplemental Table S3.4). The most common pattern of 
epicardial activation in HF patients was characterized by a normal RV activation with varying 
degrees of delay in the lateral LV. In the majority of CRT patients, the primary factors in the 
efficacy of acute resynchronization were the baseline level of LV delay and the location of the 
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LV lead. Figure 3.4 presents representative echocardiographic responders and nonresponders. 
The responders (patients 25 and 27) have high levels of baseline dyssynchrony with LV leads 
located in the region of late activation. The acute onset of CRT pacing resulted in significant 
improvement in the LV delay parameter. In contrast, the first nonresponder (patient 12) had a 
lower degree of baseline LV dyssynchrony, and the onset of pacing resulted in a smaller 
improvement in synchrony compared to the responders. The second nonresponder (patient 13) 
had a high degree of baseline dyssynchrony, however, the anterior location of this patient’s lead 
reduced the effectiveness of pacing at synchronizing the ventricles. 
 
Figure 3.4 Activation isochrone maps in CRT patients in native rhythm prior to CRT pacing and at the onset of 
pacing. Pacing lead locations in the CRT-paced images are indicated with black spheres. LV activation delay values 
in each rhythm and the decrease in the absolute value of the index (“Improvement”) are indicated to the right of the 
images. Echocardiographic responders (top 2 rows) generally had high levels of dyssynchrony at baseline, which 
was substantially improved by CRT pacing. Echocardiographic nonresponders often had less baseline dyssynchrony 
(row 3) or ineffective lead placement (row 4). 
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While baseline dyssynchrony and LV lead placement were major factors in acute 
resynchronization, the presence of scar affected the native rhythm and the efficacy of CRT 
pacing in several patients. Electrograms from regions of scar are characteristically low-amplitude 
and fractionated. By computing the number of steep downward deflections in electrograms we 
were able to quantify and visualize the electrophysiological substrate of scar. We found that HF 
patients had a higher percentage of fractionated electrograms than controls (median 1.77% in HF 
vs 0.38% in controls, p = 0.001). There were 5 patients with very high levels of epicardial 
fractionation (6 standard deviations above the control mean). Out of these 5 patients, 3 were 
nonischemic, 1 was ischemic, and 1 had mild nonosbstructive coronary artery disease. Three of 
these patients are presented in Figure 3.5. 
Patient 10 (Figure 3.5, top row) demonstrates the impact that scar can have on the native 
activation sequence. The patient has a large lateral region of fractionation (left column), and the 
patient’s native activation has a very long activation delay in the region of scar (middle column). 
The region of late activation is very small in this patient, and the onset of CRT pacing (right 
column) provides little to no improvement in synchrony. Patients 8 and 30 (Figure 3.5, middle 
and bottom rows, respectively) demonstrate the importance of lead placement in relation to scar. 
Patient 8 has an LV lead located in an inferolateral scar region, which resulted in delayed 
activation of the more anterior regions of the LV. Patient 30 had a region of scar in the basal 
lateral LV, but the patient’s LV lead was located in the center of a region of healthy 
myocardium. This patient’s synchrony improved substantially and the patient was an 
echocardiographic responder. 
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Figure 3.5  Maps of the number of deflections in each electrogram (first column), native rhythm activation (middle 
column), and CRT-paced activation (right column). Electrograms from the scar region and remote un-fractionated 
regions are provided to the left of the maps. Numbers indicate electrogram locations. Pacing electrode locations are 
indicated in the fractionation and CRT-paced activation maps with black or white spheres. Patients with high 
degrees of fractionation sometimes had atypical native rhythm activation sequences (top row). Pacing within regions 
of fractionation was less effective at activating nearby regions outside the scar (middle row). Patients with large 
regions of fractionation could still be resynchronized effectively when paced outside of the fractionated region 
(bottom row). 
 
Contraction 
Contraction in CRT patients was dyssynchronous and impaired. CRT patients had larger pre-
systolic stretch and low peak contraction amplitudes than controls (full statistical comparisons 
presented in Supplemental Table S3.3). Figure 3.6 (top) illustrates the native rhythm 
contraction sequence for a CRT patient. Electrical activation of the lateral LV is delayed relative 
to the other segments (vertical lines). The lateral LV was stretched by the septal wall contraction 
prior to its own contraction and the lateral wall segments reached peak contraction after aortic  
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Figure 3.6. Native rhythm strains in heart failure (HF) patients (top) were dyssynchronous and lower in amplitude 
than controls. Lateral regions often stretched prior to contraction and reached peak strain after aortic valve closure 
(dotted line). Many regions were later to reach peak strain (top bullseye) than controls. The mean electromechanical 
delay in HF patients was the same as in controls, but the values within the LV showed greater dispersion (bottom 
bullseye). The Acute onset of CRT (bottom) decreased pre-systolic lateral wall stretch. Peak strain timing values did 
not capture synchrony improvements effectively. Regional electromechanical delay values were not consistent 
across different activation sequences. 
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valve closure (vertical dotted line). While the overall pattern of delayed LV contraction is 
apparent from the strain curves, it is difficult to extract meaningful markers of contraction timing 
from the plots because of the influence of opposing contraction and low amplitudes in some 
regions. In this patient, several of the septal wall segments reach peak strain after the lateral wall, 
despite the apparent overall pattern of delayed LV contraction. The mean electromechanical 
delays observed in HF patients closely matched control values, however, the dispersion of 
electromechanical delays within the LV were much larger. 
The onset of CRT pacing improved the overall synchrony of the strain sequence (Figure 3.6, 
bottom). Lateral wall stretch is reduced, but peak strain values remained low compared to 
controls. The dispersion of electromechanical delay values in the LV was not corrected by the 
onset of CRT, and values within regions varied between the CRT and native rhythm. This 
indicates that the electromechanical delay cannot be regarded as an activation sequence-
independent property of the underlying tissue. 
Volumetric Reverse Remodeling 
Of the 30 CRT patients, 22 patients completed the study and could be classified as 
echocardiographic responders or nonresponders. Out of these, 7 (32%) were nonresponders, 
consistent with the rate of nonresponders observed in most CRT studies. We used Spearman’s 
rank correlation coefficient to correlate baseline native rhythm electrical and mechanical 
parameters with change in LVESV (Supplemental Table S3.5). In general, we found that 
electrical dyssynchrony parameters were much more predictive of reverse remodeling than 
mechanical dyssynchrony and function parameters. Each ECGI index of electrical dyssynchrony 
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(total activation time, LV electrical delay, and LV electrical dispersion) correlated with LVESV 
remodeling more strongly than QRS duration and all of the mechanical indices. The most 
predictive parameter was the LV electrical delay (rho = -0.722, p < 0.001). In addition to 
baseline parameters, we correlated improvements in synchrony parameters at the onset of CRT 
pacing with change in LVESV (Supplemental Table S3.6). In this evaluation, acute 
improvements to the LV activation delay and mechanical dispersion had the highest correlations 
with LVESV remodeling (rho = 0.679 and rho = 0.671, respectively). However, these 
correlations were both lower than the correlation between baseline LV delay and LVESV 
remodeling. 
Electrical and Mechanical Remodeling 
To assess changes in electrical and mechanical properties induced by chronic CRT pacing, we 
compared electrical and mechanical parameters in native rhythm prior to the onset of CRT 
pacing to native rhythm after 6 months of CRT. We found no significant changes in electrical or 
mechanical synchrony parameters when comparing native rhythm before and after chronic CRT 
pacing (Supplemental Table S3.7), indicating that the underlying level of dyssynchrony 
remains unchanged. Despite the unchanged native rhythm activation sequence, we found a 
persistent improvement in native rhythm contraction magnitudes after 6 months of CRT 
(Baseline median: -8.55%, Remodeled median: -10.14%, p = 0.008) and sustained EF 
improvement (Baseline median: 24%, Remodeled median: 27%, p < 0.001). Figure 3.7 
demonstrates the improved contraction in 4 CRT patients. 
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Figure 3.7 Peak contraction magnitudes are improved during the course of CRT. Values at each visit were 
determined from un-paced native rhythm beats, indicating persistent improvements in contraction as a result of 
chronic CRT pacing. 
 
Prior to the onset of CRT, HF patients’ mean epicardial ARIs were prolonged by about 45 msec 
compared to controls (Supplemental Table S3.3). After 6 months of CRT, mean epicardial 
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ARIs were largely unchanged (Supplemental Table S3.7). However, native rhythm ARIs near 
the LV pacing site were prolonged by a median value of 23 msec (p = 0.002). Figure 3.8 
presents baseline and remodeled ARI maps for 2 patients. 
We correlated the changes in contraction and ARI prolongation at the LV pacing site with the 
change in ESV. The change in contraction was correlated with ESV change, but the LV ARI 
change was not (Supplemental Table S3.8). This suggests that the contraction improvement is 
part of the beneficial reverse remodeling changes induced by CRT, while the ARI prolongation 
is an effect of LV pacing that is not related to the beneficial reverse remodeling process. 
 
Figure 3.8. Epicardial activation-recovery interval (ARI) maps in heart failure (left) and after 6 months of CRT 
pacing (right). Heart failure patients had longer mean ARI values than control subjects at baseline. After 6 months of 
CRT pacing, ARI values were prolonged at the location of the left ventricle (LV) pacing lead. 
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3.5 Discussion 
This paper presents the first combined application of ECGI and strain imaging in patients, 
thereby providing electrical and mechanical data from the same human hearts in situ. The 
following observations were made: 1. The LV electrical activation delay, determined from 
ECGI, outperforms mechanical measures of synchrony and is the best index for identifying 
potential responders to CRT. It also performs better than the QRS duration on the 12 – lead ECG 
that constitutes the standard of care in clinical practice. 2. Taking advantage of the panoramic 
mapping that ECGI provides, we discovered that LV pacing in CRT prolongs the APD in the 
region surrounding the electrode. The localization of the APD prolongation indicates that CRT 
pacing increases heterogeneity of repolarization, a known mechanism of arrhythmia. 3. We 
defined a novel parameter, the electromechanical delay between activation and peak strain within 
anatomical segments. We  measured greater heterogeneity of the electromechanical delay in 
patients with dyssynchronous HF than controls. We also found that the electromechanical delay 
within regions is dependent upon the activation sequence.  This implies that the timing of peak 
strains on echo does not merely reflect the electrical activation sequence, but  is affected by the 
mechanics of opposing wall contractions. This may explain, in part, why STE has not seen 
greater success as a tool for CRT patient selection. 4. Through noninvasive assessment of healthy 
adult hearts, we demonstrated that the ARI on the epicardial surface in females is longer than 
males. Further study of gender-specific differences in repolarization with ECGI may help explain 
why women are more susceptible to arrhythmias associated with the long QT syndrome. 5. Using 
tagged MRI, we provide a high-resolution 3D description of contraction of healthy hearts that is  
co-registered spatially and temporally with detailed electrical activation and repolarization maps. 
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These data could be beneficial for constraining mathematical models and validating computer 
simulations of human cardiac electromechanics. 
3.5.1 Control Physiology 
The control population in this study is the largest group of healthy adults imaged with ECGI to 
date. This group served as a control for the current study and is valuable in that capacity as ECGI 
is applied to new pathologies. Additionally, the larger size of this study compared to a previous 
ECGI study of healthy adults allowed us to quantify the difference in epicardial repolarization 
between males and females. The longer repolarization we find in females is consistent with ECG 
findings that women have longer QTc intervals than men 28. Exploring the link between this 
repolarization prolongation and the higher susceptibility of women to torsade de pointes would 
be an interesting application of ECGI 29. 
The combination of ECGI, STE, and tagged MRI provide very detailed 3D characterizations of 
the healthy adult heart in situ. Tagged MRI provides detailed 3D displacement and strain data in 
the LV, however, the exact timing of the image acquisition relative to the ECG is opaque. By 
collecting STE, which is acquired with the body-surface ECG, in the same patients, we were able 
to align the strain curves temporally using the time of peak strain in each modality. The result is 
a detailed combination of electrical and mechanical sequences in healthy adult hearts. This data 
set may be particularly useful to constrain and validate mathematical models of the cardiac 
electromechanics. 
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3.5.2 Response to CRT 
The initial evaluations of ECGI in CRT patients were retrospective studies of ischemic and 
nonischemic patients 25,26. These studies evaluated two dyssynchrony indices: the LV activation 
delay and the LV activation dispersion. In the present prospective evaluation of electrical 
dyssynchrony and response to CRT, we found that both indices out-performed the body-surface 
ECG and mechanical indices, and that the LV delay index was the best predictor of volumetric 
reverse remodeling (Supplemental Table S3.5). That is, high level of inter-ventricular 
dyssynchrony, as measured by ECGI, is a good predictor of response to CRT. This is in 
agreement with a prior prospective ECGI study of CRT patients that found the LV delay 
(referred to in that study as ventricular electrical uncoupling) was superior to QRS duration at 
identifying responders 30. A recent torso-tank study has directly validated ECGI reconstructions 
of this index compared to direct epicardial measurements 31. In this study, we found that baseline 
electrical dyssynchrony was more correlated with LVESV remodeling than the improvement of 
synchrony at pacing onset. However, it would be valuable to explore whether using ECGI 
interactively to optimize lead placement and pacing timing would offer patients additional 
benefits. 
An evaluation of ECGI in patients with pediatric congenital heart disease found that placing the 
LV lead in the site of latest activation resulted in favorable outcomes 32. The present study 
demonstrated the ability of ECGI to image electrophysiological scar and showed its influence on 
dyssynchrony and pacing efficacy. Prior studies, using other imaging modalities, have 
demonstrated the importance of scar and its location relative to pacing leads for predicting CRT 
response 33. However, ECGI offers the unique possibility of quantifying baseline dyssynchrony 
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with indices that may outperform the current standard of practice, identifying regions of delayed 
activation, imaging myocardial scar substrate, and evaluating the efficacy of lead location and 
other pacing parameters with a single imaging modality in real-time.  
3.5.3 Remodeling 
We found that contraction magnitudes increased as part of the CRT reverse remodeling process, 
and that the increased magnitudes persisted when comparing patients’ baseline native rhythm to 
their native rhythm after 6 months of CRT. This, coupled with the absence of any activation 
sequence changes, indicates that the increased contraction was due to mechanical improvements. 
Cellular studies report decreased contraction amplitudes in myocytes isolated from failing human 
hearts 2. Animal studies have reported that CRT restores intracellular Ca2+ transients to normal 
levels, which could improve contraction 11. However, Ca2+ transient changes were associated with 
a reversal of APD prolongation 11,12, which we did not observe. Another possible mechanism for 
increase in contraction amplitudes is that they are secondary to the volumetric reverse remodeling. 
In simplified models, ventricular wall stress is proportional to chamber diameter as governed by 
the Law of Laplace 34. The strong correlation between LVESV decrease and contraction amplitude 
supports this as a possible mechanism. 
Multiple animal studies demonstrated ARI shortening as a result of CRT induced reverse 
remodeling 11,12. In our study, we find not only that mean epicardial and mean LV ARIs do not 
decrease, but that at the site of the LV pacing lead native-rhythm ARIs increase by a median value 
of 23 msec. The discrepancy between our observations and the animal studies could be due to the 
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species differences, or the nature of the heart failure model, which was induced by RV tachypacing 
over a period of weeks to months. 
The ARI prolongation we observed was not strongly correlated with LVESV, suggesting that it 
may be an effect of the pacing, rather than the reverse remodeling process. Prior work showed that 
pre-excitation due to RV pacing and Wolff-Parkinson-White syndrome were both associated with 
prolonged ARI in the region of pre-excitation 35,36. In the present study, we observed ARI 
prolongation at the LV pacing site, but not the RV pacing site. It is noteworthy that CRT devices 
are often programmed so that the RV is activated by the intrinsic conduction system (illustrated in 
Figure 3.4, patients 25 and 27). This may cause less consistent pre-excitation at the RV lead 
location than the LV location and consequently a minimal effect on ARI. 
There have been conflicting reports about whether CRT reduces or increases the risk of arrhythmia 
10,37. The finding of increased dispersion of repolarization due to ARI prolongation in the region 
of pacing suggests a mechanism for CRT increasing the risk of arrhythmia. The actual influence 
of this mechanism in the context of beneficial remodeling is unclear, however, this mechanism 
may be more significant in nonresponders. Because the ARI prolongation appears to be caused by 
the LV pacing and not reverse remodeling, nonresponders may be subjected to increased 
heterogeneity in repolarization without the benefits of improved LV function, which may be 
detrimental to their overall health. This underscores the importance of clinical criteria that properly 
exclude patients who will not benefit from CRT from receiving the treatment. Given these 
observations, it would be interesting to explore whether emerging LV pacing techniques such as 
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LV endocardial pacing, which may carry additional benefits 38, have a more favorable effect on 
repolarization. 
3.5.4 Conclusion 
The data support the utility of ECGI for improving patient selection for CRT. The timing of peak 
strain in STE is not a reliable index of local activation time when dyssynchrony is present. CRT-
induced reverse remodeling improves contraction but prolongs repolarization at the LV pacing 
site, augmenting dispersion of repolarization. Additional studies are necessary to determine 
whether electrogram fractionation maps or interactive ECGI device optimization offer additional 
benefits to CRT treatment of HF patients.  
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Chapter 3 Appendix 
Supplemental Table S3.1: Control Population 
ID Age Sex Race Ethnicity 
C1 27.8 M Asian Not Hispanic 
C2 28.1 M Caucasian Not Hispanic 
C3 28.3 M Caucasian Hispanic 
C4 27.5 F Caucasian Not Hispanic 
C5 27.6 M Caucasian Not Hispanic 
C6 27.0 M Caucasian Not Hispanic 
C7 31.9 M Caucasian Not Hispanic 
C8 27.3 M Caucasian Not Hispanic 
C9 29.4 F Caucasian Not Hispanic 
C10 25.1 F Caucasian Not Hispanic 
C11 24.9 M African American Not Hispanic 
C12 49.0 F Caucasian Not Hispanic 
C13 22.1 F Caucasian Not Hispanic 
C14 35.5 M Caucasian Hispanic 
C15 24.1 M African American Not Hispanic 
C16 34.8 F Asian Not Hispanic 
C17 24.4 F Caucasian Not Hispanic 
C18 22.0 F Caucasian Not Hispanic 
C19 53.7 F Caucasian Not Hispanic 
C20 31.0 F Caucasian Not Hispanic 
 
Healthy adult volunteer demographics. 
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Supplemental Table S3.2: CRT Population 
ID Age Sex Race Ethnicity Etiology 
EM1 53.0 F Caucasian Not Hispanic NICM 
EM2 64.0 F Caucasian Not Hispanic NICM 
EM3 71.9 M Caucasian Not Hispanic NICM 
EM4 63.3 M Caucasian Not Hispanic NICM 
EM5 54.4 M Caucasian Not Hispanic NICM 
EM6 73.0 F Caucasian Not Hispanic NICM 
EM7 66.3 M Caucasian Not Hispanic ICM 
EM8 59.8 M Caucasian Not Hispanic NICM 
EM9 69.5 F Caucasian Not Hispanic NICM 
EM10 62.4 M Caucasian Not Hispanic ICM 
EM11 69.3 F Caucasian Not Hispanic NICM 
EM12 67.5 M Caucasian Not Hispanic ICM 
EM13 60.1 M African American Not Hispanic ICM 
EM14 54.5 F Caucasian Not Hispanic NICM 
EM15 77.6 M Caucasian Not Hispanic ICM 
EM16 64.0 F Caucasian Not Hispanic NICM 
EM17 52.5 M Caucasian Not Hispanic NICM 
EM18 78.7 F Caucasian Not Hispanic ICM 
EM19 74.7 F Caucasian Not Hispanic NICM* 
EM20 34.7 M Caucasian Not Hispanic NICM 
EM21 77.5 M Caucasian Not Hispanic ICM 
EM22 81.1 M Caucasian Not Hispanic ICM 
EM23 55.3 M Caucasian Not Hispanic ICM 
EM24 74.1 M Caucasian Not Hispanic NICM 
EM25 51.3 F Caucasian Not Hispanic NICM 
EM26 72.4 M Caucasian Not Hispanic ICM 
EM27 40.5 F African American Not Hispanic NICM 
EM28 62.4 M Caucasian Not Hispanic NICM 
EM29 61.4 M African American Not Hispanic NICM 
EM30 64.1 M African American Not Hispanic NICM 
 
Cardiac resynchronization therapy patient demographics. ICM: Ischemic Cardiomyopathy. NICM: Nonischemic 
cardiomyopathy 
*Mild nonobstructive coronary artery disease  
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Supplemental Figure S3.1: ECGI Methodology 
 
Schematic of the ECGI procedure. Body-surface potentials are recorded from the torso surface using a portable 
recording system (top). The heart-torso geometry is obtained using a computed tomography (CT) or magnetic 
resonance imaging (MRI) scan (bottom). The heart-torso geometry and torso potentials are combined and the 
inverse problem is solved to reconstruct unipolar epicardial electrograms. Electrograms are processed to determine 
local electrical parameters of interest (right frame). 
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Supplemental Table S3.3: Heart Failure Comparison to Controls 
 
 
Control and heart failure baseline electrical and mechanical parameter comparison. All parameters were measured in 
native rhythm. Groups were compared using Wilcoxon rank-sum tests. 
 
  
Parameter
Control
Median
Control
IQR
Heart Failure
Median
Heart Failure
IQR p
ECG QRS duration (msec) 87 16 154 31 p < 0.001
Ejection fraction (%) 57 3 24 4 p < 0.001
End systolic volume (mL) 46 20 122 56 p < 0.001
End diastolic volume (mL) 111 36 160 72 0.002
Stroke volume (mL) 63 18 39 19 p < 0.001
Total activation time (msec) 42 12 123 33 p < 0.001
LV activation delay (msec) 14 7 81 48 p < 0.001
LV activation dispersion (msec) 9 3 24 9 p < 0.001
Mean epicardial ARI (msec) 238 32 284 26 p < 0.001
Mean LV ARI (msec) 240 23 292 25 p < 0.001
Mean RV ARI (msec) 240 50 281 31 p < 0.001
Percentage of fractionated electrograms (%) 0.38 1.03 1.77 2.11 0.001
Fractionated deflections per electrogram 0.0038 0.0103 0.0179 0.0254 p < 0.001
Total strain time (msec) 98 42 196 67 p < 0.001
Mechanical delay (msec) 12 53 91 112 p < 0.001
Mechanical dispersion (msec) 28 10 70 19 p < 0.001
Mean peak strain time (msec) 427 40 432 82 0.532
Mean peak contraction (%) -20.64 2.82 -8.78 2.42 p < 0.001
Max pre-systolic stretch (%) 2.57 1.86 4.38 3.48 0.003
Mean electromechanical delay (msec) 375 40 373 50 0.940
Electromechanical delay dispersion (msec) 25 15 57 19 p < 0.001
Electromechanical Delay
Strain
Volume
ECGI
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Supplemental Table S3.4: Acute Resynchronization 
 
 
The effect of acute CRT pacing onset on electrical and mechanical parameters in heart failure patients. Changes 
were evaluated using Wilcoxon signed-rank tests. 
  
Parameter
Native
Median
Paced
Median
Paired Delta 
Median
Paired Delta 
IQR p
ECG QRS duration (msec) 154 128 -37 31 p < 0.001
Ejection fraction (%) 24 27 3 4 p < 0.001
End systolic volume (mL) 122 114 1 20 0.914
End diastolic volume (mL) 160 168 5 29 0.094
Stroke volume (mL) 39 43 7 9 p < 0.001
Total activation time (msec) 123 104 -19 29 0.004
LV activation delay (msec) 81 10 -62 53 p < 0.001
LV activation dispersion (msec) 24 29 11 2 0.057
Total strain time (msec) 196 182 -14 75 0.223
Mechanical delay (msec) 91 -15 -96 91 p < 0.001
Mechanical dispersion (msec) 70 63 -9 40 0.046
Mean peak contraction (%) -8.78 -8.78 0.22 1.97 0.549
Max pre-systolic stretch (%) 4.38 3.6 -1.23 2.19 0.009
Mean electromechanical delay (msec) 373 391 10 50 0.097
Electromechanical delay dispersion (msec) 57 61 8 33 0.039
ECGI
Volume
Electromechanical Delay
Strain
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Supplemental Table S3.5: 
 LVESV Remodeling Correlation with Baseline Parameters 
 
Correlations between the change in left ventricular end-systolic volume (LVESV) after 6 months of CRT pacing and 
baseline electrical and mechanical parameters in heart failure patients. All parameters were measured in native 
rhythm. Correlations were determined using Spearman’s Rho tests. 
 
  
Parameter Spearman's Rho p
ECG QRS duration (msec) -0.486 0.023
Total activation time (msec) -0.583 0.005
LV activation delay (msec) -0.722 p < 0.001
LV activation dispersion (msec) -0.588 0.005
Mean epicardial ARI (msec) -0.110 0.625
Mean LV ARI (msec) 0.168 0.454
Mean RV ARI (msec) -0.373 0.088
Fractionated deflections per electrogram 0.241 0.280
Fractionated deflections per electrogram at LV pacing site 0.387 0.075
Total peak strain time (msec) -0.425 0.101
Mechanical delay (msec) 0.132 0.639
Mechanical dispersion (msec) -0.585 0.019
Mean peak contraction (%) 0.009 0.978
Mean pre-systolic stretch (%) -0.324 0.221
Activation-peak strain delay (msec) -0.225 0.419
Activation-peak strain delay spread (msec) -0.204 0.466
ECGI
Strain
Electromechanical Delay
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Supplemental Table S3.6: 
LVESV Remodeling Correlation with Acute Dyssynchrony Index Changes 
 
 
Correlations between the change in left ventricular end-systolic volume (LVESV) after 6 months of cardiac 
resynchronization therapy (CRT) pacing and the change in dyssynchrony parameters due to the acute onset of CRT 
pacing. Correlations were determined using Spearman’s Rho tests. 
 
  
Parameter
Spearman's 
Rho p
ECG QRS duration (msec) 0.505 0.017
Volume Ejection fraction (%) 0.025 0.934
Total activation time (msec) 0.407 0.061
LV activation delay absolute value (msec) 0.679 p < 0.001
LV activation dispersion (msec) 0.545 0.010
Total peak strain time (msec) 0.583 0.023
Mechanical delay absolute value (msec) 0.013 0.965
Mechanical dispersion (msec) 0.671 0.008
ECGI
Strain
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Supplemental Table S3.7: 
Native Rhythm Changes after 6 Months of CRT 
  
The effects of 6 months of cardiac resynchronization therapy pacing on heart failure patients’ electrical and 
mechanical parameters. All parameters at each visit were computed from native rhythm beats. Changes were 
evaluated using Wilcoxon signed-rank tests. 
 
 
  
Parameter
Baseline
Median
6 Months
Median
Paired Delta 
Median Delta IQR p
ECG QRS duration (msec) 154 157 5 11 0.164
Ejection fraction (%) 24 27 6 7 p < 0.001
End systolic volume (mL) 125 121 -22 47 0.046
End diastolic volume (mL) 167 171 -11 49 0.306
Stroke volume (mL) 40 48 8 19 0.005
Total activation time (msec) 123 115 -4 14 0.178
LV activation delay (msec) 82 81 2 20 0.858
LV activation dispersion (msec) 24 25 1 4 0.211
Mean epicardial ARI (msec) 282 288 6 28 0.408
Mean LV ARI (msec) 288 293 6 26 0.211
Mean RV ARI (msec) 280 283 4 28 0.833
LV pacing site ARI (msec) 280 306 23 36 0.002
RV pacing site ARI (msec) 293 297 3 30 0.291
Percentage of fractionated electrograms (%) 1.54 1.85 0.56 2.16 0.511
Fractionated deflections per electrogram 0.0171 0.0235 0.0046 0.0492 0.565
Total peak strain time (msec) 196 210 14 77 0.891
Mechanical delay (msec) 88 81 -6 65 1.000
Mechanical dispersion (msec) 70 66 0 26 0.228
Mean peak contraction (%) -8.55 -10.14 -1.31 2.93 0.008
Mean pre-systolic stretch (%) 4.59 3.48 -1.13 4.22 0.438
Activation-peak strain delay (msec) 367 381 14 45 0.169
Activation-peak strain delay spread (msec) 57 50 -7 20 0.135
Volume
Strain
Electromechanical Delay
ECGI
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Supplemental Table S3.8: 
Correlation of LVESV Remodeling with ARI and Contraction Remodeling 
 
Correlation between the change in left ventricular end-systolic volume after 6 months of cardiac resynchronization 
therapy (CRT) pacing and the changes in ARI and contraction remodeling. Correlations were determined using 
Spearman’s Rho tests. 
 
  
Parameter Spearman's Rho p
LV pacing site ARI (msec) -0.206 0.356
Mean peak contraction (%) 0.618 0.013
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Chapter 4: Concluding Remarks and Future 
Work 
 
4.1 Concluding Remarks 
This thesis demonstrated the utility of ECGI as a research and clinical tool by combining ECGI 
with complimentary imaging techniques to study new patient populations. The results of this 
work revealed new aspects of human heart physiology and point to roles for ECGI in the clinical 
care of patients. 
The combination of ECGI and LGE imaging in ARVC patients revealed electrical abnormalities 
which co-localized with regions of visible scar. ARVC patients had abnormalities in conduction 
and repolarization. PVCs were common in ARVC patients, and they typically originated in 
regions of scar and electrical abnormalities. This finding implicates the electrical and structural 
abnormalities as mechanistic contributors to the formation of arrhythmia triggers in ARVC 
patients. In a young ARVC patient, we found that conduction abnormalities were visible before 
structural abnormalities. This suggests that the sensitivity of ECGI for detecting conduction 
abnormalities can play an important role in the early concealed phase of the disease. 
By combining ECGI and strain imaging in CRT patients, we demonstrated that ECGI is effective 
for predicting response to CRT. The most sensitive index for predicting response to CRT was the 
LV activation delay determined by ECGI. STE indices were less effective predictors of response. 
The time delay between electrical activation and peak contraction within anatomical regions was 
variable and rhythm-dependent in CRT patients. This indicates that mechanical factors other than 
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the activation sequence influence the time of peak strain by STE. We showed that CRT pacing 
causes improvements in contraction that persist even when the pacing is temporarily disabled. 
We also found that CRT prolongs repolarization at the LV pacing site, which could increase the 
risk of arrhythmia. 
4.2 Future Work 
There are numerous opportunities for continuing to build upon this thesis and the work that 
preceded it. In the context of ARVC, this thesis demonstrated that ECGI detects electrical 
abnormalities in ARVC and linked them to PVCs, which can trigger dangerous arrhythmias. In 
order to relate the ECGI findings to the underlying scar substrate, the study used MRI-based 
LGE. A downside of using MRI to study patients with ARVC is that patients with ICDs were 
excluded from the study group because ICDs carry a contraindication for MRI. Because patients 
with a history of arrhythmia typically receive ICDs, the study population did not include any 
patients with a history of arrhythmia. Therefore, the study could not evaluate how predictive the 
various abnormalities were of arrhythmia. An important future study would be to compare 
patients with a history of arrhythmia to those without, and then determine whether any ECGI 
indices predict the risk of arrhythmia. Currently, the only widely accepted criterion for ICD 
implantation is a history of ventricular tachycardia. Because the first occurrence of ventricular 
tachycardia can be deadly, improved predictors of arrhythmia risk in ARVC patients are urgently 
needed. 
A logical continuation of CRT research in this thesis would be to perform a larger prospective 
study to compare outcomes in patients selected for CRT by ECGI criteria to outcomes in patients 
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selected with conventional criteria. There are obvious benefits to delivering effective treatment 
to more patients. There are also benefits to accurately identifying patients who will not respond 
to the treatment. As the EchoCRT clinical trial showed, CRT may be detrimental in patients who 
do not need the treatment. Our data suggest that heterogenous repolarization may contribute to 
the detrimental effects of pacing these patients. Accurate identification of nonresponders could 
help decrease healthcare costs and direct more effective treatment strategies to nonresponders. 
Another avenue for exploration is using ECGI to optimize CRT pacing settings. The relative 
timing of pacing leads is an important factor in the overall effectiveness of pacing. Even modest 
improvements over current practices could have a very large impact because of the large 
population of heart failure patients. 
There are many important applications outside of ARVC and CRT that should be further 
explored. One of the most interesting recent developments in the field of cardiac 
electrophysiology is the emergence of noninvasive ablation. Treatment for arrhythmia is 
traditionally performed in an invasive procedure in which a catheter is guided to the heart and 
used to burn regions of tissue that are responsible for starting or sustaining arrhythmia. A recent 
pilot study performed at Washington University in St. Louis tested the use of radiation therapy as 
an alternative to the standard invasive ablation procedure 1. Noninvasive ablations were 
performed on 5 patients with ventricular tachycardia that was refractory to conventional 
treatment. Prior to ablation, the patients were mapped with ECGI, and ECGI maps were used to 
help guide the ablation target. The treatment resulted in a 99.9% reduction in ventricular 
tachycardia in the patient cohort. The combination of noninvasive electrical mapping and 
noninvasive ablation are a natural pairing, and evaluation of this approach is already underway in 
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a larger cohort. While the early results of this work are very exciting, there are many 
improvements that can be made. Improvements to the delivery of radiation should include 
incorporation of cardiac motion. Currently, the target is chosen for optimal delivery throughout 
the cardiac cycle, but unnecessary radiation delivery to healthy surrounding tissue could be 
reduced by incorporating cardiac motion. This thesis demonstrated that ECGI is compatible with 
tagged MRI, which tracks the motion of the left ventricle throughout the cardiac cycle. Beyond 
tagged MRI, the compatibility of ECGI with CT and MRI enables its combination with 
numerous other imaging techniques that could improve radiation delivery. 
Finally, the ultimate success of any clinical tool depends on evidence-based guidelines for its 
application and its cost-effectiveness for improving patient outcomes. While ECGI was applied 
purely as a research tool in this work, the technique is now commercially available. In order to 
maximize the long-term benefits that ECGI can offer, future research must continue to prove the 
benefits of clinical ECGI, and commercial development must ensure that those benefits are cost-
competitive within the context of current standards of practice.  
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